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Abstract 
Mounting evidence suggests a crucial role for vitamin D in the pathogenesis of 
type 2 diabetes mellitus (T2DM). Our objectives were to examine the correlation 
between serum calcidiol and diabetes outcomes, and determine whether vitamin 
0 3 and calcium supplementation would attenuate the severity of T2DM. Eleven 
non-white, post-menopausal women with T2DM (age, 61 ± 11 y) were 
supplemented for 3 y with either placebo or 1800 IU 03 + 720 mg calcium 
(CaD)/day. The relative change over 3 y in serum calcidiol significantly inversely 
correlated with the relative change in body weight, BMI, body fat (%), hip 
circumference, serum TC/HDL-C and serum PTH, whereas it positively 
correlated with serum calcium. Retrospective analysis showed differences 
between the CaD vs. placebo in hip circumference, serum calcidiol, serum PTH 
and systolic blood pressure. We conclude that modest improvements in vitamin 
D status may mitigate the decrement in T2DM-related sequelae in non-white, 
post-menopausal women. 
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Introduction 
1.0 Type 2 Diabetes Mellitus: Epidemiology and Background 
Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic 
disorders, with 171 million cases around the world (1 ). It is anticipated that this 
number will double by 2030 to 366 million (1). In Canada, it is expected that 3.7 
million Canadians will suffer from diabetes by 2020, with a cost of more than 15 
billion dollars (2). These numbers indicate an epidemic and call for immediate 
interventions. Diabetes patients also suffer from serious secondary illnesses 
such as coronary heart disease (CHO), blindness, kidney disease, amputation, 
and depression (3). The aetiology of T2DM is complex with a number of 
interacting genetic and environmental factors. These can be attenuated through 
lifestyle changes such as increasing physical activity and improving diet (4). 
T2DM is characterized by altered macronutrient metabolism, specifically 
glucose, protein and lipids. Glucose homeostasis is a state in which plasma 
glucose concentrations are regulated to within normal ranges, even through 
periods of fasting (S 7 .0 mmol/L) and feeding (S 11.1 mmol/L) (5). Normal 
glycaemia is mediated through two main physiological pathways: glucose 
production from the liver and glucose uptake by peripheral tissue, namely 
adipose tissue and muscle. Two key hormones regulate these physiological 
processes, respectively: glucagon and insulin. T2DM is diagnosed when fasting 
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plasma glucose (FPG) exceeds 7 mmol/L, or when plasma glucose (PG) of 
;?!11.1 mmol/L is detected 2h post-75 g oral glucose tolerance test (OGTT} (5). 
Insulin resistance (inability to respond properly to insulin) and ~-cell dysfunction 
(inability to produce insulin) are the key defects in this endocrine disorder. Insulin 
resistance precedes J3-cell dysfunction, whereby high circulating insulin levels 
are found in the plasma as a result of J3-cell compensation for increased insulin 
demand. Nevertheless, as insulin resistance progresses J3-cell function 
deteriorates. And by the time T2DM is diagnosed, individuals had lost 
approximately 80% of their J3-cell function (6-7, 179). 
1.1 Risk Factors 
Numerous risk factors contribute to the development of T2DM. Evidence 
suggests a crucial role of obesity in T2DM pathogenesis (8) as it contributes 
approximately 60% of total T2DM cost in the United States (9). Additionally, 
obesity is associated with a cluster of metabolic disorders that underlie T2DM 
pathogenesis such as: insulin resistance (10), hyperlipidemia (11 ), and 
inflammation ( 12). Other risk factors include: ethnicity ( 13), dietary habits, life 
style (14-17), and genetics (18). 
The Nurses' Health Study is a prospective cohort study that examined the 
association between adiposity and T2DM risk in women, it included follow-up 
throughout 1976-1990. It demonstrated that the increase in BMI, an important 
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marker of adiposity, was associated with increased risk for T2DM (19). The 
increase in T2DM risk was more pronounced in those who had a BMI > 30 
kg/m2 (RR %95 Cl = 27.6 [22.7 to 33.5]) and > 35 kg/m2 (RR %95 Cl = 93.2 
[81.4 to 106.6]) as compared to those with a BMI < 29 kg/m2 (19). Findings of 
the Nurses' Health Study were confirmed in another prospective study 
conducted in males (8). Waist circumference (WC), an adiposity index, was 
also positively correlated with insulin resistance (r = 0.88) in non-diabetic 
women (10). Hyperlipidemia is characterized by abnormally high lipid profile 
indices such as low-density lipoprotein (LDL) and total cholesterol (TC). High 
lipid indices correlate with obesity and contribute to T2DM pathogenesis (20). 
Some ethnic backgrounds exhibit greater susceptibility to T2DM (21-24). A 
cross-sectional study by Goff et al. examined ethnic variation in insulin 
resistance and other biomarkers in three ethnic groups: South Asians, Black 
Africans, and white Europeans (21 ). Male South Asians had significantly higher 
HOMA-IR, homeostatic model of assessment insulin resistance; a marker of 
insulin resistance, than white European men by 49% (P < 0.001 ). Female 
South Asians and Black Africans showed higher HOMA-IR than white 
European women by 15. 7% (P = 0.015) and 32.8% (P = 0.021 ), respectively 
(21 ). Black African women have 9.8% higher body fat(%) (P = 0.024) than 
South Asians, and significantly lower lipid profile indices: total cholesterol by 
13%, LDL-C by 14%, triacylglycerol by 42%; than South Asian women. 
3 
Nevertheless, after adjustment for gender, age, and BMI, South Asians and 
Black Africans had significantly lower insulin sensitivity assessed by intra-
venous glucose tolerance test (IVGTT) (21 ). High insulin resistance in South 
Asians was confirmed in another meta-analysis that examined the 
pathogenesis of T2DM in this group (22). 
Lastly, genetic predisposition is a key risk factor in T2DM. The Finnish Twin 
Cohort Study examined the genetic aspects of chronic disease development, 
such as T2DM. Forty-one pairs of twins were included in the analysis to 
determine the heritability of insulin sensitivity and insulin secretion (25). IVGTT 
and euglycemic hyperinsulinaemic clamp were used to assess insulin secretion 
(first and late response) and insulin sensitivity. In monozygotic twins, insulin 
secretion positively correlated with heritability (first response r = 0.55, and late 
response r = 0.66) (25). Moreover, whole-body insulin sensitivity also positively 
correlated with heritability (r = 0.46) (25). Findings of this study confirmed the 
strong effect of heritability on two predominant contributors (decreased insulin 
secretion and insulin sensitivity) to T2DM pathogenesis. 
1.2 Pathophysiology 
T2DM is a multifaceted endocrine disorder in which alterations in different 
metabolic pathways and hormones contribute to the pathophysiology. Insulin 
resistance and J3-cell dysfunction are the two main key defects in T2DM etiology. 
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Other underlying metabolic defects include: oxidative stress, lipotoxicity, 
glucotoxicity and systemic inflammation. 
1.2.1 Insulin Resistance 
Insulin, a potent anabolic hormone, is produced by the pancreatic ~-cells 
of the islets of Langerhans. It regulates carbohydrates, protein and lipid 
metabolism. Insulin action is mediated through alterations in cell proliferation 
(26), gene expression (27), and apoptosis (28). For proper glucose uptake, 
multi-step insulin signaling must occur. Elevated plasma glucose concentration 
results in bi-phasic insulin release in an electrogenic fashion (29). It relies on two 
key ion channels: KA TP and Ca2+ voltage-sensitive channels. A rapid first 
response is initiated after the entry of glucose into the J3-cells by glucose 
transporters-2 (GLUT-2), which is mediated by glucose-induced KATP channel 
inhibition causing cell depolarization. Cell membrane depolarization results in the 
opening of Ca2+ voltage-sensitive channels, allowing Ca2+ influx and insulin 
exocytosis (30,31 ). 
Once insulin is released into circulation, it binds to the cell surface insulin 
receptor (IR) on peripheral tissues, resulting in the autophosphorylation of 
tyrosine ~-subunits. Insulin receptor substrates (IRS1/2) are then 
phosphorylated, and hence activated, to act on phosphatidylinositol 3'-kinase 
(Pl3K), an important signaling molecule. The activation of Pl3K will ultimately 
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facilitate glucose entry into the cell through the translocation of GLUT-4 to the 
cell membrane (32). Insulin resistance develops when the above mechanism is 
altered and target peripheral tissues (muscle and adipose tissue) are unable to 
respond properly to insulin secretion (32). There are several proposed 
mechanisms underlie insulin resistance: alteration in lipid metabolism, activation 
of unfolded protein response (UPR), and systemic inflammation (33). 
Collectively, these mechanisms result in altered insulin receptor phosphorylation 
(an increase in serine and threonine phosphorylation and decrease in tyrosine 
phosphorylation) and signaling pathways (34). 
1.2.2 13-cell Dysfunction 
J3-cells are an important component of the endocrine system, and play a 
key role in T2DM pathogenesis. Impaired J3-cell function is pronounced in T2DM 
pathogenesis in both younger and older patients, and features high 
concentrations of plasma pro-insulin (an insulin precursor) (35). A recent study 
by Elder et al. compared ~-cell preservation in T2DM adults (52.3 ± 2.8 y), 
healthy adolescents (14.5 ± 0.3 y) and newly T2DM-diagnosed adolescents 
(15.8 ± 0.5 y) (35). The disposition index, a measure of ~-cell function, was 
significantly lower by== 900% in both T2DM groups compared to healthy 
adolescents (35). In T2DM, ~-cell function is compromised, and hence insulin 
secretion is reduced. The decline in ~-cell function can be explained through the 
decrease in J3-cell mass. A unique study by Butler and colleagues was 
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conducted on 124 human pancreata autopsies to understand the aetiology of J3-
cell deficit in T2DM (36). This study suggested that increased J3-cell apoptosis is 
responsible for the observed decrease in J3-cell mass. Frequency of J3-cell 
apoptosis was significantly higher in lean diabetics by 571 % compared to their 
BMI matched non-diabetic controls (36). In-vitro studies attribute ~-cell apoptosis 
to the high expression of nitric oxide synthase (iNOS) and subsequent 
production of nitric oxide (NO) (37). NO plays an integral role in ~-cell 
destruction, since it mediates the pro-apoptotic cytokines TNF-a, IL-1 J3, and INF-
V (37). 
1.2.3 Other Underlying Metabolic Defects 
Glucotoxicity. or persistent hyperglycemia, is believed to decrease insulin 
secretion (altered J3-cell function) and insulin sensitivity (altered insulin signaling 
pathways) (38,39). Persistently high glucose aggravates J3-cell dysfunction 
through: 1) the increased production of reactive oxygen species (ROS), which 
are deleterious at high concentrations, resulting in decreased antioxidant 
enzyme expression, such as that of superoxide dismutase (SOD 1 and 2) and 
glutathione peroxide (GPx-1) (11,38); 2) the disturbances in insulin signaling 
pathways that include decreased tyrosine, IRS-1 and Pl3K phosphorylation, and 
increased serine and threonine phosphorylation (40); and 3) the activation of 
UPR, as an adaptive response of stressed endoplasmic reticulum (39). 
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Lipotoxicity: It is well-established that the accumulation of ectopic free fatty-
acids, active fatty acid derivatives that are not stored in adipose tissues, 
contribute to insulin resistance and inflammation ( 41,42). The significance of 
insulin is not limited to its action on glucose metabolism but it is also an 
important hormone that regulates lipid metabolism. Lipotoxicity occurs when 
insulin's inhibitory effect on hormone sensitive lipase (HSL), which facilitates fat 
mobilization, is suppressed (43). Insulin action, signaling and receptor 
accessibility is highly affected by lipotoxicity ( 41 ,44 ). 
Inflammation: Clinical evidence demonstrates increased production of 
inflammatory cytokines from adipose tissues, such as tumor necrosis factor 
(TNF- a), interleukin-6 (IL-6), and interleukin-10 (IL-10) (12). 
1.3 Treatment and prognosis 
Once an.individual is diagnosed with T2DM by meeting the diagnostic 
criteria determined by the Canadian Diabetic Association (FPG;:::: 7.0 mmol/L, or 
2h PG in a 75-g OGTT ;:::: 11.1 mmol/L, or random PG ;:::: 11.1 plus classic 
diabetes symptoms) (5), the main goal is to lower the elevated serum glucose 
levels (hyperglycemia) that are a hallmark in diabetic patients. This can be 
achieved through different mechanisms depending on the choice of 
pharmaceutical drugs. Insulin and oral hypoglycemic agents (i.e., metformin) are 
the main medical interventions for diabetic patients and are crucial for reducing 
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macro- and micro-vascular complications ( 45). Also of importance are non-
medically based treatments such as exercise and improved nutrition. 
Nutritional- and lifestyle-based interventions demonstrate positive effect on 
diabetes outcome measures through attenuation of some of the underlying 
mechanisms, such as inflammation (inflammatory cytokines) (46,47) and 
dyslipidemia (lipid indices), or improving overall glycemic control (i.e. lowering 
glucose levels, decreasing HbA1c, and improving lipid profile) (14). Nutritional 
interventions aim to control carbohydrate and fat intake and distribution, increase 
physical activity, and promote weight loss. The aforementioned approaches 
resulted in a reduction of approximately 1-2% in HbA 1 c, an important indicator of 
glycemic control over the prior- 3 months (14), and a reduction in diabetes risk 
(15). In a clinical intervention, a very low-carbohydrate or a low-fat diet were 
assigned to obese men (mean ±SD for age 33.2 ±11.3 y, and BMI 34.3± 5.6 
kg/m2) for 8 weeks to study inflammation biomarkers (46). A significant decrease 
in absolute inflammatory biomarkers was observed in both the low-carbohydrate 
and low-fat groups: hsCRP (-55%, P < 0.001; and -48%, P < 0.001 ;respectively), 
hsTNF- a (-45%, P < 0.001; and -42%, P < 0.001; respectively), and hsll-6 (-
51 %, P < 0.001; and -46%, P < 0.001; respectively) compared to baseline values 
(46). In another clinical trial, Dekker and colleagues concluded that increased 
physical activity results in decreased IL-6 concentration and waist circumference 
in obese and lean men with or without T2DM (16). Moreover, surgery- or dietary-
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induced weight loss improved glycemic control (17). Diet and exercise have also 
shown to delay T2DM progression in subjects with impaired glucose tolerance 
(IGT) (48). In a meta-analysis that compared the effect of diet, exercise, and 
pharmacological interventions in reducing T2DM risk, diet (HR 95% Cl = 0.67 
[0.49 to 0.92]) and exercise (HR 95% Cl = 0.49 [0.32 to 0. 7 4]) interventions had 
comparable risk to that of pharmacological interventions (HR 95% Cl = 0. 70 
[0.62 to 0.79]) (48). 
2.0 Vitamin D 
2.1 Vitamin D functions 
Vitamin D is a fat-soluble vitamin, however its actions can be considered 
as those of a hormone. The traditional role of vitamin D is to maintain calcium 
and phosphorus homeostasis through facilitation of intestinal calcium absorption 
and renal reabsorption ( 49). The intestine is one of the main classical target 
organs for vitamin D action. Intestinal calcium absorption is mediated through 
genomic and non-genomic effects of circulating 1,25(0H)203 (calcitriol, the most 
active form of vitamin D). Calbindin, a calcium binding-protein responsible for 
calcium transportation, is synthesized in response to increased gene expression 
in epithelial cells (50) as a result of vitamin D stimulation which exemplifies a 
genomic action of vitamin D. This is also the case in the kidneys which are 
another classical target organ for vitamin D (50). Nevertheless, due to the 
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presence of the vitamin 0 receptor (VOR) throughout body tissues, vitamin 0 
function is not limited to mineral regulation and bone health, and is not limited to 
a few select organs (51,52). Empirical evidence suggests vitamin 0 plays a role 
in cell differentiation, cell proliferation, immunomodulation, muscle health, 
cardiovascular health, anti-inflammation, and fertility (52,53). 
2.2 Vitamin D metabolism 
Uniquely, vitamin 0 can be obtained through diet either in the form of 
ergocalciferol (02) from plants or from animal-based dietary sources in the form 
of cholecalciferol (Vitamin 03). Vitamin O content in food is very limited, hence 
dietary sources are insufficient to fulfill vitamin O recommendations (54). 
Exposure to sunlight, specifically UVB rays (wavelengths ~ 290-315 nm), is the 
main natural source of vitamin 03 during the summer months (June- July) in the 
northern hemisphere (latitude ~ 42°N) (55). Exposure to summer sunlight at 
noon for 15-90 minutes in northern latitudes will significantly increase serum 
calcidiol levels (55). Exposure to sunlight will result in photolytic conversion of 7-
dehydrocholesterol (7-0HC), a precursor synthesized from cholesterol and found 
within the epidermal layer of the skin, to previtamin 03. Subsequently, previtamin 
0 3 is isomerized by thermal induction to form vitamin 0 3 (56,57). Vitamin 03 
receives two successive hydroxylations to achieve the highest degree of 
activation; one performed in the liver by vitamin 0-25-hydroxylase (25-0Hase) to 
form 25(0H)03 (also known as calcidiol) (58,59) and another performed in the 
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kidneys by 25-hydroxyvitamin 03-1-ahydroxylase (1-aOHase) to form 1,25 
dihydroxyvitamin 0 3 (1,25 (OH)2D3) (59,60). The latter hydroxylation produces 
the most active metabolite of vitamin D, which is known as calcitriol (61 ); 
however, the former hydroxylation produces the most stable form. Furthermore, 
once 1,25(0H)2D3 is formed, it binds to the VDR to exert a wide-spectrum of 
biological effects in different body tissues that possess VDR. The production of 
calcitriol is not exclusive to renal production, as 1-aOHase is also found in other 
body organs such as colon (62), breast (61 ), parathyroid gland (62), and brain 
(63), allowing for the local production of this metabolite. Vitamin D action results 
in both genomic and rapid non-genomic actions (64 ). At the cell membrane, the 
binding of VDR ligands to the VDR results in rapid non-genomic actions; such 
as, an increase in intracellular Ca levels (65,66). In the cell, vitamin D and its 
metabolites bind to the VDR in the nucleus and form a heterodimer with retinoid 
X receptor (RXR). Consequently, the VDR-RXR complex binds to the vitamin D 
response element (VORE) (67,68) and initiates a cascade of events ranging 
from calcium metabolism to increased gene expression (65). 
2.3 Vitamin D deficiency 
Worldwide, vitamin D deficiency is a major health risk. Initially, the 
recommended intake and optimal status for vitamin D were based on optimal 
bone health and fracture prevention (69). Generally, calcidiol levels below 50 
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nmol/L are considered deficient or insufficient, but not optimal (70-72). Vitamin 
D is involved in various metabolic pathways that underlie a number of chronic 
diseases (66). Higher levels of serum calcidiol levels in human and animal 
studies (> 75 nmol/L) improve health outcomes related to T2DM (73, 7 4 ), multiple 
sclerosis (MS) (75), amyotrophic lateral sclerosis (ALS) (76-78), and some 
cancers (79,80). It is also suggested that an increase in serum calcidiol from 45 
to 110 nmol/L may reduce global morality risk by approximately 20% from 
chronic diseases that have been linked to vitamin D deficiency (81 ). This is in 
agreement with another recent analysis of the NHANES Ill data which concluded 
that when combined with increased Mg intake serum calcidiol inversely 
associated with cardiovascular and colorectal mortality (82). A number of 
observational studies linked vitamin D deficiency to a wide range of chronic 
diseases, such as type 1 and 2 diabetes mellitus (83,84 ), and metabolic 
syndrome (85). 
2.4 Vitamin D status controversy and recommended intake: 
The Institute of Medicine (IOM) (71) published the most recent vitamin D 
Recommended Dietary Allowance (RDA) in 2010 (see Table 2). Nevertheless, to 
date there has been little agreement on what is considered deficient, sufficient, 
or optimal in terms of serum calcidiol concentrations. Suggested cut-off points 
for serum calcidiol status are summarized in Table 1. Difficulties arise; however, 
when an attempt is made to implement a general recommended intake of 
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vitamin D for a population with a wide range of health issues (see 'Vitamin D 
Deficiency'). There is, therefore, a definite need for specific recommendations for 
groups/subgroups with different ethnicities, ages, health/disease status and 
gender. Von Hurst et al concluded that optimal serum calcidiol concentrations 
that would reduce insulin resistance were between 80-119 nmol/L (86). In 
addition, serum calcidiol is affected by multiple factors: age, season, ethnicity, 
latitude, sun light exposure, and medical conditions (51,87). 
In 2010, the Canadian Health Measure Survey (CHMS) reported vitamin 
D status by assessing serum calcidiol levels in 5,306 Canadians aged 6-79 y 
representing 28.2 million Canadians from all regions. Mean serum calcidiol was 
67. 7 nmol/L, with one-third with more than 75 nmol/L (87). 
Table 1: Vitamin D status controversy (values refer to serum calcidiol 
concentrations) (71,72,88). 
Halick et al, 2011 < 50 nmol/L 52.5-72.5 nmol/L > 72.5 nmol/L 
Hanley et al, 2010 < 25 nmol/L 25-75 nmol/L > 75 nmol/L 
Ross et al, 2011 < 27 .5 nmol/L 27.5-50 nmol/L > 50 nmol/L 
Table 2: Vitamin D Recommended Dietary Allowance (RDA) by IOM (values are 
IU of vitamin D per day) (54). 
400 IU/d 
600 IU/d 
> 70 years 800 IU/d 
Durin regnancy and Lactation 600 IU/d 
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2.4.1 Vitamin D and seasonal variation 
According to CHMS, Canadians had lower concentrations of serum 
calcidiol in November-March than in April-October by 8.5% (87). A retrospective 
study conducted by Christensen et al intended to examine the variations in 
serum vitamin D and PTH resulting from age and seasonal changes in 1551 
subjects in Western Norway. During the winter months and early spring, low 
serum calcidiol concentrations (25-49 nmol/L) were observed in 38% of the 
population while 43. 7% of the population had serum calcidiol concentrations 
exceeding 75 nmol/L during summer months (89). Seasonal negative effect on 
serum calcidiol levels is confirmed in the literature (90-93) due to the insufficient 
UVB-radiation for dermal calcitriol production. 
2.4.2 Vitamin D and age 
7- dehydrocholestrol photolysis is the very first of multiple steps in 
generating calcitriol, however the production of this cholesterol derivative 
molecule decreases with aging (94). The cutaneous production of calcitriol is an 
age-dependent process that is decreased with increasing age, resulting in low 
levels of plasma calcitriol (94 ). Of interest, serum calcidiol concentration followed 
a U-shape pattern by age according to CHMS. Boys aged 6-11 y and male 
seniors 60-79 y had higher serum calcidiol (76.8 nmol/L and 70 nmol/L) than 
adult males aged 20-39 y (60. 7 nmol/L) (87). A global meta-analysis revealed 
that the mean serum calcidiol levels are 17.5% lower in subjects aged > 75 y 
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than those who are 15-65 y (mean ± SEM: 47 ± 4.0 nmol/L vs. 57 ± 1.8 nmol/L; 
respectively) (95). These results coincide with those of the NHANES Ill whereby 
subjects who were 40-59 y and ~ 60 y had lower serum calcidiol levels than 
those who were 20-39 y (71. 7 ± 1.0 and 69.5 ± 0.9 nmol/L vs. 81.0 ± 1.1 nmol/L, 
respectively; P < 0.0001 for both) (84). 
2.4.3 Vitamin D and Ethnicity 
Ethnicity is a strong determinant of vitamin D status, and its effect on 
serum calcidiol concentrations has been examined in the literature in a wide 
range of ethnic backgrounds (96). Dark-skinned individuals have substantially 
lower levels of vitamin D than individuals with lighter skin, even after considering 
seasonal variations (93,97,98). CHMS reported that Canadians of white racial 
background had 27% higher calcidiol concentration than other ethnic 
backgrounds (87). In 126 healthy, normoglycemic individuals, whites had 47.9% 
higher calcidiol concentration than Asian Americans (P = 0.0226) (98). Harris 
and colleagues investigated plasma calcidiol seasonal fluctuations in two ethnic 
groups: white (n = 39 and age 31.7 ± 6.1 y) and Black (n = 51 and age 30.6 ± 
5.9 y) women (99). During the winter (February-March) and summer (June-July) 
months, Black women had lower plasma calcidiol concentrations by 49.6% and 
51.9% (P < 0.005), respectively (99). This difference is attributed to the 
decreased dermal production of vitamin D3 in Black individuals due to increased 
skin pigmentation (96). Furthermore, non-hispanic Black and Mexican 
16 
Americans had significantly lower concentrations of serum calcidiol by 38.3% 
and 17%, respectively, than non-hispanic white (P < 0.0001) (84 ). 
2.4.4 Vitamin D and Adiposity 
Adiposity has a negative effect on vitamin D status. Studies have shown 
that body fat is inversely associated with serum calcidiol (90,98, 100). A 
population-based study conducted by Snijder et al in 2005 using 453 participants 
aged 65 y or older found that total body fat (TBF) percentage was strongly 
associated with lower serum calcidiol and higher PTH levels for both men and 
women (P < 0.001) ( 100). In women, those in the highest serum calcidiol quartile 
(52.9 nmol/L) had lower total body fat (TBF 22.3%) compared to those in the 
lowest quartile (40.2 nmol/L; with TBF 48.2%) (100). These results coincide with 
another 16-week randomized clinical trial by Dong et al where 49 normotensive 
Black boys and girls aged 16.3 ± 1.4 y were randomly allocated to either a 
control (400 IU/d of vitamin 03) or treatment group (2000 IU/d of vitamin 0 3) 
(101 ). Results showed an exponential increase in vitamin D levels in the 
treatment group at 8 and 16 week (70.9 ± 22.0 and 85. 7 ± 30.1 nmol/L, 
respectively) compared to baseline (33.1 ± 8. 7 nmol/L) ( 101 ). TBF mass (kg) 
was inversely correlated with serum calcidiol in the treatment group at baseline 
and throughout the study (101 ). This strong association between adiposity and 
serum calcidiol might be explained by the fact that adipocytes are the main site 
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for vitamin D storage (102). Increased fat would decrease the amount of 
endogenously-produced vitamin D in the circulation. 
2.4.5 Vitamin D and parathyroid hormone (PTH) 
Parathyroid hormone (PTH) and vitamin D are extremely important 
regulators of calcium homeostasis. In response to low serum calcium levels, the 
parathyroid gland releases PTH into the circulation. Higher levels of PTH 
facilitates: 1) the second required hydroxylation of vitamin D in the kidneys to 
form calcitriol (103), 2) calcium mobilization from the bone (bone resorption) 
(104), and 3) calcium absorption in the intestine (105). Vitamin D and PTH have 
an inverse relationship (91, 100). 
3.0 Potential Mechanisms for the Effects of Vitamin D on T2DM 
Vitamin D supplementation may have a significant effect on T2DM 
pathophysiology. This might be possible through enhancing insulin secretion via 
facilitation of J3-cell biosynthetic capacity, improving insulin sensitivity, and 
reducing inflammatory response. These effects are not exclusive to the glycemic 
pathways but rather to multiple metabolic pathways that would indirectly 
attenuate T2DM severity. 
Blood pressure: Blood pressure is regulated through the modulation of the renin-
angiotensin system. In an animal study, mice were either fed vitamin D sufficient 
or deficient chow for 6 weeks, followed by a high fat (HF) diet for 8 weeks to 
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evaluate the effect of vitamin D deficiency on systolic and diastolic blood 
pressure (SBP and DBP) and atherosclerosis (106). At baseline and after 8 
weeks of HF diet, vitamin D deficient mice had significantly higher SBP (by== 
15% and 10.7%, respectively) and DBP (by== 25.9% and 7.7%, respectively) 
(106). Moreover, African women with low serum calcidiol levels(< 74.7 nmol/L) 
have higher SBP and DBP (by 9.5% and 6%, respectively) than those with 
sufficient serum calcidiol levels(> 74.7 nmol/L) (107). 
Improving lipid profile: CVD complications in diabetic patients can be decreased 
through improving blood lipid profile, and lowering body weight through the 
suppression of PTH (108). Calcitriol suppresses macrophage cholesterol uptake 
and decreases foam cell formation (109). In vitamin D-deficient media, cultured 
macrophages of obese, hypertensive, diabetics had increased foam cell 
formation and increased cholesterol uptake compared to those cultured in 
vitamin D-supplemented media (110). Moreover, other lipid profile biomarkers 
(i.e. LDL-C and TGs) have negative association with serum calcidiol (85). Lastly, 
the consumption of vitamin D fortified yogurt (1000 IU/d) for 12 weeks resulted in 
significant decrease in WC and BMI (P < 0.001) (111 ). 
3.1 Pancreatic P-cell function and insulin secretion 
The vitamin D receptor has been identified in pancreatic ~-cells (112). In-
vitro studies suggest local production of calcitriol in pancreatic islets, through the 
action of 1-aOHase (113). Vitamin D facilitates the biosynthetic capacity of~-
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cells through genomic modulation (114) and rapid non-genomic pathways (115). 
Chui et al investigated the association between vitamin D status and J3-cell 
function in healthy, normoglycemic subjects (98). During OGTT, they found a 
negative correlation between calcidiol concentrations and glucose levels at 
fasting (P = 0.0258), 60 min (P = 0.0011 ), 90 min (P = 0.0011 ), and 120 min (P = 
0.0007) (98). These findings indicate poor J3-cell compensation under low 
calcidiol concentration, i.e. in low vitamin D status. Furthermore, vitamin D 
facilitates insulin secretion indirectly through intracellular calcium trafficking 
(115). In-vitro studies indicate that insulin secretion is a Ca-dependent process, 
and an acute increase in intracellular Ca2+ induces insulin exocytosis ( 116) that 
represents the rapid non-genomic action of vitamin D. Animal studies have 
shown that insulin secretion is improved when vitamin D levels are normalized 
(114, 117). 
3.2 Insulin Resistance 
Insulin resistance is a key player in the development of T2DM, and it is an 
important pathogenic factor underlying elevated fasting glucose levels. As insulin 
resistance progresses, there is an increase in the levels of free fatty acids 
(FFAs) due to the suppression of insulin's inhibitory effect on FFA release from 
the liver (118). In subjects with T2DM, plasma FFA concentrations are 
significantly higher by 10-70% (P < 0.05-0.01) during graded hyperinsulinemia 
tests than their matched controls after a 12 h overnight fast (119). Elevated 
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circulating FFAs decrease insulin-stimulated peripheral glucose uptake and 
increase hepatic glucose output into the blood (120). Furthermore, FFAs impair 
insulin release through their effects on pathways involved in cell signaling (121 ). 
Collectively, insulin resistance significantly contributes to the metabolic 
syndrome from a glycemic perspective. Moreover, it is associated with a number 
of metabolic abnormalities such as obesity (46) and dyslipidemia (5). Vitamin 0 
facilitates gene transcription of the insulin receptor (IR) gene through its genomic 
actions (123) and up-regulates GLUT-4 translocation (124). In healthy, centrally 
obese men, vitamin 0 3 supplementation (120,000 IU/d fortnightly for 6 weeks) 
improved insulin sensitivity calculated using the oral glucose insulin sensitivity 
(OGIS) in the treatment group by 138% (125). 
3.3 Systemic Inflammation 
Accumulating evidence suggests a strong association between T20M and 
inflammation. Moreover, the immunomodulatory effect of vitamin 0 has been 
established. Calcitriol suppresses the expression of inflammatory cytokines 
through its genomic action on specific tissues (126). In a 12-week randomized 
clinical trial by Shab-bidar et al., subjects who were assigned to vitamin 0-
fortified yogurt (500 IU vitamin 0 3 and 170 mg calcium/250 ml, twice per day) 
exhibited a significant decrease in TNF-a, IL-6 and CRP (45%, 89% and 51 %, 
respectively) compared to those who were assigned plain yogurt ( 127). 
Furthermore, they had higher concentration of IL-10 (25%), an anti-inflammatory 
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cytokine, compared to the control group ( 127). A recent cross-sectional study 
has revealed a negative correlation between serum calcidiol concentrations and 
oxidative stress/inflammation markers such as oxidized LDL (r = -0.413, P = 
0.001) and advanced oxidation protein products (r = -0.475, P < 0.001) in 
subjects with diabetes or IFG (128). 
4.0 Literature Review 
A considerable amount of literature has been published on the 
association between vitam.in D and T2DM. The Nurse Health study conducted by 
Pittas and colleagues examined the relative risk for T2DM incidence (73). The 
lowest relative risk (RR = 0.67) for T2DM incidence was achieved when vitamin 
0 3 and calcium intake exceeded 800 IU/d and 1200 mg/d, respectively (73). This 
section of the thesis reviews the literature concerning the effectiveness of 
vitamin D repletion on glycemia, starting with epidemiological studies, through 
prospective and human clinical trials, and lastly, animal models. 
4.1 Epidemiological Studies 
In the Third National Health and Nutrition Examination Survey (NHANES 
Ill), Scragg et al. investigated the association between serum calcidiol and the 
risk of T2DM, and whether this association, if any, varies by ethnicity (84 ). This 
survey showed an inverse association between diabetes (risk factors or 
prevalence) and serum calcidiol in non-Hispanic whites (OR 95% Cl = 0.25 [0.11 
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to 0.60]) and Mexican Americans (OR 95% Cl = 0.17, [0.08 to 0.37]) after 
adjusting for age, sex, BMI, leisure activity and seasonality (84). This association 
was confirmed by other epidemiological studies that examined the association 
between calcidiol levels and T2DM incidence or glycemic biomarkers (i.e. fasting 
insulin and fasting glucose, etc.) ( 129-132). The Kuopio lschaemeic Heart 
Disease Risk Factor study (KIHD) examined the association between diabetes 
biomarkers, T2DM risk and vitamin D deficiency (129). This cross-sectional 
study analyzed serum calcidiol levels of a total of 850 men and 906 women, 
aged 53-73 y. Subjects were classified according to their vit~min D levels. Those 
who had higher serum calcidiol leyels (51 - 112.8 nmol/L), had significantly lower 
levels of fasting insulin, fasting blood glucose, and OGTT 2h glucose by 16. 7%, 
1.4%, and 5.1 %, respectively, than those with lower calcidiol levels (8.5 - 34.4 
nmol/L) after adjusting for age, gender, and examination year (129). These 
associations with fasting insulin and fasting blood glucose were weakened by 
further adjustment for BMI, WHR, smoking, leisure-time physical activity, intake 
of fruits and vegetables, family history of diabetes, and examination month (129). 
Findings of the KIHD study indicate an important possible role for vitamin D in 
glucose metabolism; it is an essential nutrient for health that modulates glucose 
homeostasis. Nevertheless, vitamin D levels did not affect diabetes incidence or 
prevalence in the KIHD study which coincides with another cross-sectional study 
in the general population in Denmark (130). Using an ethnically diverse sample 
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in Toronto and London, Ontario, Canada, serum calcidiol levels were inversely 
associated with traditional components of the metabolic syndrome; namely, 
fasting insulin (P < 0.001) and TGs (P < 0.001) after adjusting for age, sex, 
ethnicity, season, PTH, physical activity, nutrient supplementation, and waist 
circumference (85). 
4.2 Prospective Studies 
There is a large volume of published prospective studies assessing the 
role of vitamin D in T2DM pathogenesis. A longitudinal observational follow-up 
study by Joerginson and colleagues evaluated the effectiveness of vitamin D 
status as a predictor of albuminurea progression and all-cause and 
cardiovascular mortality in T2DM patients (133). Over 15 y of follow-up, severe 
vitamin D deficiency was associated with 2 fold greater all-cause and 
cardiovascular mortality (HR= 1.96 [1.29-2.98] and 1.95 [1.11-3.44], 
respectively) (133). However, severe vitamin D deficiency failed to predict 
diabetic kidney disease (133). Another 5-year prospective study was conducted 
on non-diabetic Asians at high risk for T2DM to assess vitamin D deficiency's 
effect on T2DM incidence (134). Participants were divided according to their 
vitamin D status as follows: deficient(< 24 nmol/L), insufficient (25-50 nmol/L), 
and sufficient(~ 50 nmol/L). After adjusting for BMI, WC, IGI and HOMA-IR, a 
negative correlation was found between poor vitamin D status and T2DM 
incidence ( 134 ). Those who were vitamin D deficient were 3 fold more likely to 
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develop T2DM than their sufficient counterparts (HR 95% Cl = 3.23 [1.66 to 
3.60]) (134). These results corroborate another 6-y prospective study in which 
those who developed T2DM had lower serum calcidiol concentration by 11 % 
compared to those who did not develop T2DM (135). Serum calcidiol has also 
been examined as a predictor for future glycemic status in 524 non-diabetic men 
and women (mean± SD, age 52.9 ± 7.7 y) (136). Age- and sex-adjusted 
baseline mean serum calcidiol levels were 60.2 ± 25.3 nmol/L (136). After 10 y 
follow-up, serum calcidiol was inversely associated with the 2h glucose tolerance 
test(~ 95% Cl= -0.0094 [-0.004 to 0.0002]), fasting insulin(~ 95% Cl= -0.1447 
[-0.261 to -0.028]), and HOMA-IR(~ 95% Cl = -0.005 [-0.01 to -0.001]), after 
adjusting for age, sex, smoking, season, BMI, PTH, calcium, and IGF-1 (136). 
This association was confirmed in another study that examined the association 
of baseline serum calcidiol with insulin resistance, ~-cell function (evaluated 
using IGl/IR which is calculated by dividing insulinogenic index IGI by HOMA-IR 
and by using insulin secretion sensitivity index-2 ISSl-2), and glucose regulation 
in pre-diabetic 489 participants (M/F, age 50 ± 10 y; BMI 30.33 ± 4 kg/m2) (137). 
At the 3 year follow-up and with respect to baseline serum calcidiol, IGl/IR and 
ISS-2, measurements used to asses ~-cell function, had a positive association 
per unit increase in calcidiol (~ 95% Cl = 0.005 [0.0009 to 0.008] and 0.002 
[0.003 to 0.003], respectively) and a negative association with AUC glucose during 
OGTT (~ 95% Cl = -0.001 [-0.002 to -0.0003]), after adjusting for age, sex, 
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ethnicity, and season of blood draw to measure 25(0H)03. The study also 
revealed that participants who remained at normal glucose tolerance had higher 
serum calcidiol concentration by 12% in comparison to participants who became 
dysglycemic at the follow up (59.84 ± 23.07 nmol/L vs. 53.03 ± 23.1 nmol/L, 
respectively; P = 0.0041) (137). Prospectively, the association between serum 
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calcidiol and T20M or Mets risk has been demonstrated ( 138-141 ), whereas in 
others it has disappeared after further adjustment for adiposity (137)(142), or 
has been rejected (143). 
4.3 Human Clinical Trials 
Clinical trials are needed to establish the role of vitamin 0 
supplementation with respect to glycemia. In the last decade, clinical 
interventions that examined the effect of correcting vitamin D deficiency on 
diabetic markers were conducted in a wide range of ethnic groups: Blacks (144), 
whites ( 145), South Asians (86) and in Middle Eastern countries ( 111, 146). 
Vitamin 0 3 dosage in these trials ranged from a fairly low dose (400-800 IU/d) 
(145, 147) to doses reaching the upper tolerable intake (2000-4000 IU/d) 
(101, 148). In these studies, baseline serum calcidiol concentrations were either 
deficient or insufficient (15-50 nmol/L), and most values increased following 
supplementation to optimal levels (75-120 nmol/L). Von hurst et al. conducted a 
randomized, placebo controlled, double-blind intervention study, with subjects 
assigned to either a 4000 IU/d vitamin 0 3 or placebo for 6 months (86). Vitamin 
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D3 supplementation significantly increased the serum calcidiol median (from 21 
to 75 nmol/l) as compared to the placebo group (from 19 to 29 nmol/l) (86). As 
well, supplementation improved insulin sensitivity (measured by homeostatic 
model assessment for insulin sensitivity HOMA-2%S) by 41 % at 6 months in 
subjects (n = 16) whose calcidiol levels reached > 80 nmol/l (P = 0.003). Insulin 
resistance (measured by HOMA-IR) was also significantly reduced by 11. 7% (P 
= 0.02), however no differences were observed in insulin secretion between the 
two groups (86). In a randomized clinical trial by Nikooyeh et al., subjects were 
randomly divided into three groups: vitamin D + calcium fortified yogurt (DCY; 
500 IU vitamin D3 and 250 mg Ca/250 ml), vitamin D fortified yogurt (DY; 500 IU 
vitamin D3 and 150 mg Ca/250 ml), or plain yogurt (PY; no vitamin D3 and 150 
mg Ca/250 ml) twice per day for 12 weeks (111 ). The DY and DCY groups 
experienced a significant decrease in fasting serum glucose (FSG= -12.9 ± 33. 7 
mg/dl, P = 0.015; and -9.6 ± 46.9 mg/dl P = 0.035, respectively), HbA 1 c (-0.4 ± 
1.2%, P < 0.001; and -0.4 ± 1.9%, P < 0.001, respectively) and HOMA-IR (-0.6 ± 
1.4, P = 0.001; and -0.6 ± 3.2, P < 0.001, respectively) compared to PY. 
Furthermore, a significant decrease in BMI (-0.9 ± 0.6 kg.m2, P < 0.001; and -0.4 
± 0.7 kg/m2 , P = 0.005, respectively) and waist circumference (-3.6 ± 2.7 cm; 
and -2.9 ± 3.3 cm; P < 0.001 for both, respectively) was observed in DY and 
DCY compared to PY (111 ). The 16-week randomized, placebo controlled, 
double-blind Calcium and Vitamin D for Diabetes Mellitus ( CaDDM) trial 
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assigned 92 white adults at high risk of T2DM to either calcium ( 400 mg twice 
daily), vitamin 03 (2000 IU once daily), or their matching placebo (101 ). Vitamin 
03 supplementation significantly improved the disposition index (a marker of~­
cell function; derived as the product of insulin secretion and insulin sensitivity) by 
138% (adjusted mean change± SE: 300 ± 130 compared with -126 ± 127 for 
placebo P = 0.011 ), and increased insulin secretion (62 ± 39 mU• L-1 •min 
compared with -63 ± 37 mU• L-1 •min for placebo; P = 0.046), with a non-
significant decrease in HbA1C (%) (149). It is worth noting that calcium 
supplementation did not change any of the measured outcomes. 
To examine the effect of vitamin D and calcium supplementation on T2DM 
incidence in postmenopausal women, The Women's Health Initiative was 
conducted in 2008 and considered one of the largest intervention human studies 
with 33,951 healthy post-menopausal women aged 50-79 y (73). Women were 
assigned to either the treatment (1000 mg elemental calcium and 400 IU vitamin 
03 daily) or placebo group (73). The authors concluded that vitamin D and 
calcium supplementation had no effect on T2DM incidence. However, the 
vitamin D dose ( 400 IU/d) was relatively low (lower than the current RDA for 
vitamin D) and may not have been enough to detect an effect on T2DM 
incidence. Recently, researchers investigated the safety and efficacy of the 
upper tolerable dosage of vitamin 0 3 supplementation (4000 IU/d) (86, 144, 148). 
Harris and colleagues investigated the effect of 12 weeks of vitamin 0 3 
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supplementation on glycemic markers, namely insulin sensitivity, insulin 
secretion and the disposition index, in 89 overweight and obese African 
Americans with diabetes or prediabetes (148). Following a randomized, placebo 
controlled design; subjects were allocated to either the treatment (4000 IU/d of 
vitamin 03) or placebo group. A significant increase (P < 0.001) in vitamin D 
status in the treatment group (40 to 81 nmol/L) was observed (148). 
Unexpectedly, insulin sensitivity significantly decreased (P < 0.034) in the 
treatment group by 4% and increased by 12% in the placebo group (148). A 
dosage of vitamin 0 3 supplementation of 4000 IU/d for 6 months reduced 
HOMA-IR by 27% (P = 0.033) and improved QUICKI, a measure of insulin 
sensitivity, by 18% (P = 0.016) in obese adolescents (144). However, there was 
no effect on FPG, HbA1c, CRP, and IL-6 (144). 
4.4 Animal Studies 
What we know about vitamin D and its relation to diabetes is largely 
based upon animal studies that investigated the underlying mechanisms of 
vitamin D action. In 1980, Norman and colleagues conducted the very first study 
that examined vitamin D's potential in controlling glycemia (150). In response to 
a glucose-arginine perfusion, uremic vitamin D deficient rats experienced 49% 
decrease in 1st phase insulin response and 4 7% decrease in 2nd phase insulin 
response compared to vitamin D replete rats (P < 0.05) (150). These findings 
were promising and opened a new window in this field. Another animal model 
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study compared FBG between 3 groups of mice: control (n = 8), diabetic (n = 8), 
diabetic and supplemented with vitamin D3 (0.28 IU/mg/d; n = 8) (151 ). After 15 
days, animals were sacrificed and those that were supplemented with vitamin D3 
had a 24% significant decrease in FBG compared to their diabetic counterparts 
(190 mg/dl vs. 250 mg/dl, respectively) (151 ). These findings are suggestive of 
vitamin D's role in attenuating diabetes severity through improving glycemic 
biomarkers. Importantly, vitamin D was examined from a therapeutic perspective 
as well as from a preventative perspective. In another animal model study, mice 
were divided in 4 groups, 10 mice in each: control (Cont), alloxan-induced 
diabetic (Diab}, diabetic that received 5000 IU/kg bw/d calcitriol after diabetes 
induction (VDther), and diabetic that received 5000 IU/kg bw/d calcitriol prior to 
alloxan injection (VDprev) ( 152). Plasma insulin was significantly lower by 59% 
and 44% in the Diab group and VDther compared to the Cont group (P < 0.001 
for both) (152). However, VDprev experienced a significant increase in plasma 
insulin by 98% (P < 0.01) accompanied by a significant 45. 7% decrease in 
plasma glucose (P < 0.01) compared to the Diab group. The decrease in plasma 
glucose was also significant in VDther compared to Diab group (P < 0.01) (152). 
When SOD activity was examined in renal and hepatic tissues, VDther and 
VDprev groups had significantly higher activity (P < 0.05 and P < 0.001, 
respectively) compared to the Diab Group. In addition, significantly higher GPx 
activity was also observed ( 152). 
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6.0 Rationale 
Current research suggests an association between vitamin D deficiency 
and type 2 diabetes (153). There is a gap in the literature regarding the effect of 
vitamin D and calcium supplementation in T2DM patients of diverse ethnicities. 
In our study, we aim to investigate the effect of vitamin D and calcium 
supplementation in T2DM patients of ethnic minorities in the GTA, Ontario. 
This study is designed to determine whether vitamin D and calcium 
supplementation would attenuate the severity of T2DM through improving fasting 
insulin, fasting glucose, glycemic control, and HOMA-IR, as well as changes in 
medications, anthropometric measures and other outcome measures. 
7 .0 Objectives 
The objectives of this study are to determine whether: 
1- Vitamin D status correlates with T2DM outcomes, 
2- Vitamin 0 3 and calcium supplementation attenuates the severity of T2DM 
by improving glycemic biomarker (fasting insulin, fasting glucose, HbA 1 c, 
and HOMA-IR), lipid profile (total cholesterol, LDL-C, HDL-C, TGs, and 
total cholesterol/HDL-C ratio), and anthropometric measures (body 
weight, waist and hip circumference, systolic and diastolic blood pressure) 
in ethnically diverse, post-menopausal women. 
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8.0 Hypothesis 
We hypothesized that subjects assigned to the treatment group would 
experience an improvement in serum calcidiol, fasting serum glucose and 
insulin, insulin resistance and J3-cell function measured by homeostatic model 
assessment, lipid profile, and anthropometric measures. 
9.0 Methods 
9.1 Study Design and Subject Recruitment 
T2DM patients were recruited at the Women's Health in Women's Hands 
Community Health Centre (WHWH-CHC), and allocated to two groups following 
a double-blind, placebo-controlled fashion: vitamin D and calcium (CaD; 
AgaeCal Inc, Vancouver, BC, Canada) or placebo. For ethical reasons,T2DM 
patients with deficient levels of vitamin D were assigned to the CaD group; 
however, subjects remained blinded. The rest of the subjects were assigned 
randomly to either placebo or CaD group. Recruitment was done by coordinating 
with WHWH-CHC personnel. The study details were clearly explained to the 
study subjects and written consent was provided before study commenced (see 
Appendix B). This study was approved by both the York University Research 
Ethics Board (certificate# 2009-055) and Health Canada (Protocol #220). 
Baseline blood work and anthropometric measures were recorded prior to 
supplementation at baseline and at 3 years. Demographic data were pulled from 
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WHWH-CHC intake forms (Table 3). Compliance was measured verbally by 
asking subjects if they were taking the placebo and CaD pills. Subjects 
completed a 3-day dietary record at baseline and at the 3-year timepoint. All 
participants were not on insulin therapy throughout the study duration. 
Table 3: Demographic characteristics of trial participants (n = 11 ). 
n (%) 
Ethnicity 
South Asian 1 (9.1) 
Caribbean 7 (63.6) 
Black 3 (27.3) 
Education 
Elementary (grades 1-8) 5 (45.5) 
High school (grades 9-12 or 13) 5 (45.5) 
University, community college, trade 1 (9.1) 
school apprenticeship 
Household 
Couple without children 1 (9.1) 
Live alone 4 (36.4) 
Siblings 1 (9.1) 
Extended family 1 (9.1) 
Grandparents with grandchildren 1 (9.1) 
Single parent family (mother) 3 (27.3) 
Income 
1000-14999 3 (27.3) 
15000-19999 5 (45.5) 
20000-24999 1 (9.1) 
30000-34999 2 (18.2) 
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9.2 Subject Selection and Withdrawal 
9.2.1 Subject Inclusion Criteria 
Non-white, post-menopausal women diagnosed with T2DM, who have an 
attending physician, and use the services of WHWH-CHC. 
9.2.2 Subject Exclusion Criteria 
Subjects diagnosed with the following were excluded from the study: 1) 
Chronic (such as liver, kidney, cancers, etc) or neurodegenerative diseases 
(such as ALS, Alzheimer's disease, multiple sclerosis), 2) any disease/condition 
that can affect T2DM, insulin function or glucose metabolism, 3) osteomalacia, 
osteopenia and/or osteoporosis, or 4) celiac disease or allergies toward gluten. 
Furthermore, participants who already supplemented with vitamin 0 3 and 
calcium (except for a multi vitamin/mineral supplement) were excluded from the 
study. 
9.2.3 Subject Withdrawal Criteria 
Subjects were withdrawn from the study if they 1) reported adverse 
effects, or 2) were diagnosed with chronic disease that may affect T2DM, insulin 
function or glucose metabolism. 
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9.3 Main Outcome Measures 
At baseline and the 3-year follow-up visit, a wide range of blood tests and 
anthropometric measurements were performed for each participant, as follows. 
9.3.1 Anthropometric Measurements 
The registered nurse at the WHWH-CHC performed anthropometric 
measurements for participants at the clinic. Weight and height were assessed 
using weight scale and height rod, and body mass index was calculated. Total 
body fat (kg) and body fat percentage was measured by using bioelectrical 
impedance analysis (BIA) (OMRON® HBF-306CCAN) (154). Waist and hip 
circumference were measured by using measuring tape: waist circumference 
was measured an inch above the belly button and hip circumference was 
measured at the widest area of the hips, and waist-to-hip ratio was calculated. 
Blood pressure (systolic and diastolic) readings were measured while seated. 
9.3.2 Blood Tests 
Fasting blood was analyzed for: serum calcidiol to assess vitamin D 
status, glycemic biomarkers (fasting serum glucose and insulin, and glycated 
hemoglobin) HOMA-IR (a measure of insulin resistance) and HOMA-B (a 
measure of beta-cell function) were calculated from fasting glucose and insulin 
values (155); lipid profile (triglycerides-TG, total cholesterol-TC, LDL-C, HDL-C, 
and TC/HDL-C ratio); parathyroid hormone (PTH); liver function tests (aspartate 
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transaminase-AST, alanine transaminase-ALT,); and serum calcium and 
albumin, and kidney function tests (serum creatinine, and estimated glomerular 
filtration rate-eGFR). Participants received lab requisitions either through mail or 
when they presented for their regular follow up visits at the center. 
9.3.3 Nutritional Assessment 
All participants completed a 3-day (2 weekdays and 1 weekend) diet 
record at baseline and 3-year follow-up visit. 
9.4 Supplementation Dosage 
Participants received a 3-month supply of a daily dose of four pills, 
containing either placebo or CaD. Treatment pills each contained each, 450 IU 
of vitamin 03 and 180 g of calcium, for a total of 1800 I U of vitamin 0 3 and 720 
mg of calcium per day. The intervention dosage was based on previous clinical 
interventions that detected an improvement in glycemic biomarkers 
(86, 111, 149). Vitamin 03 and calcium intake among Canadians was also 
considered. The mean intake of vitamin 0 3 and calcium from dietary sources and 
supplements is 412 I U/d and 1063 mg/d ( 156, 157). The supplementation in this 
study does not exceed the tolerable upper level established by the IOM. 
9.5 Statistical Analysis 
A total of 11 subjects were included in the final analysis; these included 
those who had completed all blood tests and anthropometric measurements at 
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baseline and at the 3-year follow-up visit. Due to the small sample size, non-
parametric tests were used to analyze pre and post treatment data. One-tailed 
Spearman's rank correlation coefficient was used to examine the association 
between calcidiol levels and all dependent outcome measures, because we a 
priori hypothesized that the treatment group would achieve an improvement in 
glycemic control based on previous studies (86, 111, 125, 144, 146, 147,149). All 
subjects were included in the following one-tailed bivariate correlations: serum 
calcidiol levels vs body weight, body mass index (BMI), total body fat (kg), % 
body fat, waist circumference (WC), hip circumference (HC), waist-to-hip ratio 
(WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting 
serum glucose (FSG), fasting serum insulin, glycated hemoglobin A 1c(HbA1 c), 
HOMA-IR, HOMA-8, triglycerides (TG), total cholesterol (TC), LDL-cholesterol 
(LDL-C), HDL-cholesterol (HDL-C), total cholesterol/HDL-C ratio (TC/HDL-C), 
parathyroid hormone (PTH), aspartate transaminase (AST), alanine 
transaminase (ALT), serum calcium, serum albumin, serum creatinine, and 
estimated glomerular filtration rate ( eGFR). Bivariate correlations were 
performed for values at baseline, 3 years, and both absolute and relative change 
over 3 years vs baseline. 
The Wilcoxon-signed rank test was used to detect within-group 
differences, and the Mann-Whitney test was used to detect the between-group 
differences. Analysis was conducted twice: following the per-protocol method 
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based on the original treatment group assignment, and following the 
retrospective method based on the increase in serum calcidiol concentration. 
The percentage change in serum calcidiol levels was calculated for all subjects, 
and those who had at least a 20% increase in serum calcidiol levels at the 3-y 
mark as compared to their baseline values were included in the treatment group. 
After implementing per-protocol method, 2 subjects who had 2% and 9% 
increase in serum calcidiol were reassigned to the placebo group. One subject 
who had a 42.9% increase in serum calcidiol reassigned to the treatment group; 
the subject was contacted and confirmed the consumption of 2000 IU D3'day for 
the last 3 years. Compliance was also appraised by considering the decrease in 
PTH levels in all subjects who were included in the treatment group after the per-
protocol method was implemented. Statistical analyses were performed using 
SPSS 21 (version 21, IBM). Significance was considered at P :5 0.10, and trends 
were considered at 0.10 < P :5 0.15. Data are presented as means ± standard 
deviation (SD) and medians (percentiles 25%-75%). (Check appendix A for 
parametric tests). 
Diet intake was analyzed using Diet Analysis™+ (version 8.0) for the 3 d 
diet record at baseline and at the 3-year follow-up. Mean intake of 
macronutrients (kilocalories, total carbohydrates, total protein, total fat, mono-
and poly- unsaturated fat, cholesterol) and micronutrients (vitamin D and 
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calcium) was calculated. Descriptive statistics were used to describe 
demographic data of trial participants. 
10.0 Challenges and limitations 
The main weakness of the current pilot study was the small sample size, which 
limited the applicability of its results to the general population. The most 
important challenge lies in the fact that CHC policy did not allow the researcher 
to contact CHC clients for follow-up. This resulted in low-response rate, poor 
compliance, and missing outcome measures. A number of additional issues 
were not addressed in the study design and also contributed to poor compliance. 
Firstly, the low socio-economic status of the participants presented several 
challenges regarding adhering to follow-up visits to the CHC, as the 
transportation expenses caused an economic burden. Secondly, the study 
subjects verbally self-reported compliance to the registered nurse without 
providing empty bottles to confirm compliance, violating our instructions as per 
the study design; a matter made difficult to remedy because the CHC would not 
allow our researchers contact with the study subjects. Thirdly, supplementation 
dosage was divided into four pills per day which was likely difficult for the 
subjects to adhere to; this was a matter related to pill manufacturing by AgaeCal 
Inc (Vancouver, BC, Canada). Lastly, although the length of the current study 
would establish the role of chronic CaD supplementation on aspects of T2DM 
pathology (a disease characterized by systemic anomalies in metabolism), and 
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hence strengthen the results in theory, the long duration of this human clinical 
trial resulted in a high rate of drop out. 
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11.0 Results 
Simple descriptive statistical analysis was used to investigate the effect of 
vitamin 03 and calcium supplementation on a wide range of glycemic control 
biomarkers. Baseline characteristics are presented as medians and percentiles 
following per-protocol (Table 4) and retrospective (Table 5) methods. Three-
year, subject characteristics are presented as medians percentiles following per-
protocol (Table 6) and retrospective (Table 7). Median serum calcidiol 
concentrations were 54 and 106 nmol/L at baseline and 66 and 79 nmol/L after 3 
years; for Cao and placebo, respectively for per-protocol method. 
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Table 4: Baseline characteristics presented as medians (percentiles 25%-75%) 
following per-protocol method, for T2DM subjects (n = 11 ). 
Age (years) 68 (50.5-72.7) 57 (49-69) 
Body weight (kg) 91.9 (82.9-95.0) 73.5 (58.0-84. 7) 0.109 
BMI (kg/m2) 34. 7 (33.8-36.6) 27.7 (24.8-34.9) 0.164 
Total body fat (kg) 30.9 (27.9-31.9) 24. 7 (19.5-28.5) 0.109 
Body fat(%) 35.4 (29.3-42.1) 32.5 (28.5-42.5) 1.000 
WC (cm) 101.0 90.3-108.0 89.5 (83.0-109.0) 0.527 
HC (cm) 126.0 101.5-131.4 116. 0 ( 1 01 . 0-121 . 0) 0.164 
WHR 0.84 (0.77-0.92) 0. 79 (0. 76-0.92) 0.788 
SBP (mmHg) 126.0 119.5-144.5 135.0 (115.0-140.0) 0.927 
DBP (mmHg) 80.0 78.5-84.5 85.0 (80.0-90.0) 0.527 
Serum Calcidiol 106.5 (92.3-125.3) 54.0 (43.0-67.0) 0.006 
nmol/L 
FSG (mmol/L) 7.3 (6.8-8.9) 7.0 (6.0-9.1) 0.788 
Fasting serum 67.0 (47.3-561.5) 65.0 (21.0-143.0) 0.788 insulin mol/L 
HbA1C (%) 7.1 (6.7-7.9) 7.5 (6.8-9.4) 0.527 
HOMA-IR 21. 7 (14.3-232.5) 20.2 (5.6-43.2) 0.527 
HOMA-B 384.0 (260.4-1946. 7) 178.6 (23.5-866. 7) 0.315 
TG (mmol/L) 0.83 (0.71-1.07) 1.01 (0.87-1.45) 0.315 
TC (mmol/L) 3.91 (2.83-5.08) 5.17 ( 4.60-5.86) 0.109 
LDL-C (mmol/L) 2.23 (1.11-3.36) 3.33 (2.56-3. 79) 0.230 
HDL-C (mmol/L) 1.44 (1.36-1.56) 1.40 (1.13-1. 77) 1.000 
TC/HDL-C 2.63 (2.01-3.51) 3.56 (2.60-4.20) 0.164 
mmol/L 
PTH (pmol/L) 7. 5 (6.6-9.1) 5.0 ( 4.1-8.3) 0.230 
AST (U/L) 20.5 (16.8-22.8) 22.0 (21.0-30.0) 0.412 
ALT (U/L) 15.0 (13.5-20.3) 21.0 (19.0-38.0) 0.230 
Serum calcium 2.4 (2.3-2.5) 2.4 (2.3-2.5) 0.927 
mmol/L 
43.0 (39.0-45.5) 41.0 (37.8-45.0) 0.648 
70.5 (68.3-95.3) 79.0 (70.0-84.0) 0.412 
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eGFR 
ml/min/1. 73m2 73.5 (53.5-86.0) 69.0 (64.0-78.0) 0.648 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-8, homeostatic model assessment of ~-cell function; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total 
cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. *P is significant S 0.10. 
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Table 5: Baseline characteristics presented as medians (percentiles 25%-75%), 
following retrospective method, for T2DM subjects (n = 11 ). 
ALT (U/L) 22.0 (14.0-30.0) 19.0 (14.5-40.3) 0.792 
Serum calcium 
2.4 (2.3-2.5) 2.3 (2.3-2.4) 0.247 (mmol/I) 
Serum albumin 
40.0 (37.9-45.0) 43.0 (39.7-45.3) 0.662 (g/L) 
Serum creatinine 
76.0 (68.5-91.5) 75.5 (69.8-84.0) 0.792 (µmol/L) 
eGFR 
(ml/min/1.73m2) 69.0 (56.5-79.5) 73.0 (63.8-79.3) 0.792 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-8, homeostatic model assessment of (3-cell function; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total 
cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. *P is significant :s; 0.10. 
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Table 6: Subjects characteristics at 3 y, presented as medians percentiles, 
following per-protcol assignment, for T2DM subjects (n= 11) 
Body weight (kg) 92.6 (88.6-98.5) 76.0 (57.5-84.5) 
BMI 37.1 (33.8-38.2) 32.0 (24.6-35.1) 
Total body fat (kg) 20.1 (19.2-21.4) 16.5 (12.5-18.3) 
Body fat(%) 44.6 (42.6-45.8) 38.1 (21.7-44.1) 
WC (cm) 104.1 (101.2-108.4) 96.5 (71.0-104.0) 
HC (cm) 121.9 (117.4-128.2) 108.0 (106.0-116.8) 
WHR 0.86 (0.80-0.91) 0.89 (0.84-0.96) 
SBP (mmHg) 135.5 (125.3-160.0) 137 .0 (110.0-147 .0) 
DBP (mmHg) 77.5 (68.5-87.25) 91.0 (71.0-95.0) 
Serum calcidiol (nmol/L) 79.0 (50.3-145.3) 66.0 (58.0-88.0) 
FSG (mmol/L) 6.9 (4.3-9.7) 6.4 (5.8-6.8) 
Fasting serum insulin 
53.5 (29-281.25) 83.0 (40.0-108.0) (pmol/L) 
HBA1C (%) 7.9 (7.4-8.8) 7.5 (6.7-9.6) 
HOMA-IR 21.3,(8.8-49.1) 27.8 (6.3-31.6) 
HOMA-B 213.0 (151.1-53618.0) 242.4 (71.4-765.5) 
TG (mmol/L) 0.82 (0. 75-1.08) 1.14 (0.90-1.27) 
TC (mmol/L) 3.25 (2.57-4.97) 4.58 (2.82-5.12) 
LDL-C (mmol/L) 1.48 (1.01-2.84) 2.25 (1.04-3.17) 
HDL-C (mmol/L) 1.41 (1.29-1.73) 1 . 40 ( 1 . 17 -1 . 51 ) 
TC/HDL-C 2.45 (1.88-2.87) 2.59 (2.20-3.76) 
PTH (pmol/L) 7. 5 ( 5. 3-1 0. 7) 3.7 (3.5-5.2) 
AST (U/L) 18.0 (14.3-18.8) 17.0 (13.0-25.0) 
46 
ALT (U/L) 14.0 (13.0-21.0) 17.0 (15.0-23.0) 
Serum calcium (mmol/L) 2.5 (2.3-2.6) 2.4 (2.3-2.4) 
Serum albumin (g/L) 44.5 (44.0-45.8) 41 . 0 ( 41 . 0-4 7. 0) 
Serum creatinine 65.5 (58.0-94.0) 72.0 (67.0-75.0) 
eGFR 78.5 (52.3-95.8) 73.0 (61.0-75.0) 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-B, homeostatic model assessment of ~-cell function; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total 
cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. 
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Table 7: Subject characteristics at 3 y, presented as medians (percentiles), 
following per-protocol, for T2DM subjects (n = 11) 
Body weight (kg) 95.0 (86.3-99.4) 74.5 (55.5-85.5) 
BMI (kg/m2) 37 .1 (35.8-37 .8) 29.7 (23.8-32.5) 
Total body fat (kg) 20.6 (18.7-21.6) 16.2 (12.0-18.5) 
Body fat(%) 44.1 (42.4-45.6) 34.6 (21.5-42.7) 
WC (cm) 104.0 (102.8-107.8) 92.7 (63.3-104.1) 
HC (cm) 121.9 (116.8-127.0) 107.0 (101.1-117.4) 
WHR 0.86 (0.82-0.91) 0.87 (0.83-0.96) 
SBP (mmHg) 136.0 (122.0-163.0) 129.5 (114.5-143.3) 
DBP (mmHg) 7 4.0 (70.5-86.5) 91.0 (67 .5-95.5) . 
Serum calcidiol (nmol/L) 69.0 (47.0-81.0) 77.0 (59.5-113.0) 
FSG (mmol/L) 6.8 (4.7-9.0) 6.4 (5.5-7.8) 
Fasting serum insulin (pmol/L) 100.0 (53.5-232.5) 44.5 (18.3-90.0) 
HbA1C (%) 7.5 (7.1-8.6) 8.2 (7.0-9.8) 
HOMA-IR 27 .8 (21.3-43. 7) 9.2 (5.1-33. 7) 
HOMA-B 606.1 (213.0-36169.6) 187 .2 (-354.8-373.2) 
Triglycerides (mmol/L) 0.90 (0. 78-1.21) 1.08 (0. 7 4-1.33) 
TC (mmol/L) 2.67 (2.54-4.43) 4.85 (3.58-5.41) 
LDL-C (mmol/L) 1.05 (0.98-2.54) 2.43 (1.81-3.28) 
HDL-C (mmol/L) 1.29 (1.21-1.41) 1.50 (1.32-1.96) 
TC/HDL-C 2.20 (1.97-3.33) 2. 75 (2.43-3.42) 
PTH (pmol/L) 6.3 (4.8-10.0) 3.8 (3.5-5.1) 
AST (U/L) 18.0 (13.0-22.0) 17.5 (12.5-23.3) 
ALT (U/L) 17.0 (13.0-23.0) 16.0 (13.0-23.0) 
Serum calcium (mmol/L) 2.5 (2.3-2.5) 2.4 (2.3-2.4) 
Serum albumin (g/L) 44.0 ( 42.5- 46.0) 43.5 (40.5-46.5) 
Serum creatinine (µmol/L) 70.0 (62.0-88.5) 70.5 (61.0-76.0) 
eGFR (ml/min/1.73 m2) 71.0 (58.0-86.5) 7 4.0 (67 .8-86.5) 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-B, homeostatic model assessment of ~-cell function; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total 
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cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate 
One-tailed bivariate correlations were performed including all subjects at 
baseline, all subjects at 3 years, as well as with both absolute change and 
percentage change from baseline. At baseline, serum calcidiol negatively 
correlated with TG, TC, LDL-C, TC/HDL-C (P = 0.095, P = 0.051, P = 0.063, and 
I 
P = 0.071) (Figure 2). A negative trend was observed between serum calcidiol 
and HbA 1 c (P = 0.148) (Figure 2). Non-significant negative correlations were 
observed between serum calcidiol and SBP, DBP, FSG, HbA1c, HDL-C, AST, 
ALT, and serum creatinine. Also, non-significant positive correlations were 
observed between serum calcidiol and body weight, BMI, TBF (%),WC, HC, 
WHR, fasting serum insulin, HOMA-IR, HOMA-8, serum calcium, serum 
albumin, and eGFR (See Table 8 and figures 1, 2, and 3). 
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Table 8: Spearman's rank coefficient bivariate correlations at baseline, for 
serum calcidiol, with the different outcome measures (n = 11 ). 
Body weight (kg) 0.355 0.142 0.284 
BMI (kg/m2) 0.355 0.142 0.284 
Total body fat (kg) 0.355 0.142 0.285 
Body fat(%) 0.036 0.458 0.916 
WC (cm) 0.105 0.380 0.760 
HC (cm) 0.336 0.156 0.312 
WHR 0.127 0.355 0.710 
SBP (mmHg) -0.119 0.363 0.726 
DBP (mmHg) -0.248 0.231 0.463 
FSG (mmol/L) -0.064 0.426 0.852 
Fasting serum insulin (pmol/L) 0.255 0.225 0.450 
HbA1c (%) -0.346 0.148 0.296 
HOMA-IR 0.236 0.242 0.484 
HOMA-B 0.300 0.185 0.370 
TG (mmol/L) -0.427 0.095 0.190 
TC (mmol/L) -0.519 0.051 0.102 
LDL-C (mmol/L) -0.491 0.063 0.126 
HDL-C (mmol/L) -0.232 0.246 0.492 
TC/HDL-C -0.473 0.071 0.142 
PTH (pmol/L) 0.264 0.217 0.434 
AST (U/L) -0.156 0.323 0.646 
ALT (U/L) -0.275 0.206 0.412 
Serum calcium (mmol/L) 0.255 0.224 0.448 
Serum albumin (g/L) 0.329 0.162 0.324 
Serum creatinine (µmol/L) -0.210 0.268 0.536 
eGFR (mUmin/1. 73 m2) 0.114 0.369 0. 738 
BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FSG, fasting serum glucose; 
HbA 1 C, glycated hemoglobin A 1 c; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-B, homeostatic model assessment of J3-cell function; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; PTH, 
parathyroid hormone; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, 
estimated glomerular filtration rate. *P is significant =5 0.10. 
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Figure 1: Correlations between baseline serum calcidiol (nmol/L) and baseline A) body 
weight (kg), B) body mass index (BMI, kg/m2), C) body fat(%), D) waist circumference 
(WC, cm), E) hip circumference (HC, cm), F) waist-to-hip ratio (WHR), G) systolic blood 
pressure (SBP, mmHg), and H) diastolic blood pressure (DBP, mmHg), for 11 T2DM 
patients (open circles, placebo; solid circles, CaD; according to per-protocol method). 
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Figure 2: Correlations between baseline serum calcidiol (nmol/L) and baseline A) 
fasting serum glucose (mmol/L), 8) fasting serum insulin (pmol/L), C) glycated 
hemoglobinA 1 c (HbA 1 c, % ), D) homeostatic model assessment of insulin resistance 
(HOMA-IR), E) homeostatic model assessment of J3-cell function (HOMA-8), F) 
triglycerides (TG, mmol/L), G) total cholesterol (TC, mmol/L), H) low-density lipoprotein 
cholesterol (LDL-C, mmol/L), I) high-density lipoprotein cholesterol (HDL-C, mmol/L), 
and J) total cholesterol/HDL-C ratio (TC/HDL-C, mmol/L), for 11 T2DM patients (open 
circles, placebo; solid circles, CaD; according to per-protocol method). 
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Figure 3: Correlations between baseline serum calcidiol (nmol/L) and baseline A) 
parathyroid hormone {PTH, pmol/L), B) aspartate transaminase (AST, U/L), C) alanine 
transaminase (ALT, U/L), D) serum calcium (mmol/L), E) serum albumin (g/L), F) serum 
creatinine (µmol/L), and G) estimated glomerular filtration rate ( eGFR, mUmin/1. 73 m2) 
for 11 T2DM patients (open circles, placebo; solid circles, CaD; according to per-
protocol method). 
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At the 3-year time point, serum calcidiol was negatively correlated with 
DBP and HbA 1 c (P = 0.073 and P = 0.046) (Figures 4 and 5), and positively 
correlated with serum calcium (P = 0.078) (Figure 6). A negative trend was 
observed between serum calcidiol and FSG (P = 0.119) (Figure 5). Negative 
non-significant correlations were observed between serum calcidiol and body 
weight, BMI, TBF, WC, HC, WHR, SBP, FSG, HOMA-IR, HOMA-8, ALT, and 
serum creatinine. Moreover, positive non-significant correlations were observed 
between serum calcidiol and fasting serum insulin, TG, TC, LDL-C, HDL-C, 
TC/HDL-C, PTH, AST, serum albumin, and eGFR (See Table 9 and Figures 4, 
5, and 6). 
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Table 9: Spearman's rank coefficient bivariate correlations at 3 y, for serum 
calcidiol with the different outcome measures (n = 11 ). 
-0.164 0.315 0.630 
-0.155 0.325 0.650 
-0.164 0.315 0.631 
-0.009 0.489 0.978 
-0.087 0.400 0.800 
-0.239 0.239 0.478 
-0.182 0.296 0.592 
-0.127 0.355 0.710 
-0.469 0.073 0.146 
-0.388 0.119 0.238 
0.036 0.458 0.916 
-0.533 0.046 0.092 
HOMA-IR -0.118 0.365 0.730 
HOMA-8 -0.200 0.278 0.556 
0.045 0.447 0.894 
0.278 0.204 0.408 
0.155 0.325 0.650 
0.209 0.269 0.538 
0.287 0.196 0.392 
0.041 0.452 0.904 
0.212 0.266 0.532 
-0.170 0.309 0.618 
0.458 0.078 0.156 
0.083 0.404 0.808 
-0.073 0.416 0.832 
eGFR ml/min/1. 73 m 0.005 0.495 0.990 
BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FSG, fasting serum glucose; 
HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-B, homeostatic model assessment of ~-cell function; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; PTH, 
parathyroid hormone; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, 
estimated glomerular filtration rate. P is significant~ 0.10. 
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Figure 4: Correlations at 3 years between serum calcidiol (nmol/L) and A) body weight 
(kg), B) body mass index (BMI, kg/m2), C) body fat (BF,%), D) waist circumference 
(cm), E) hip circumference (cm), F) waist-to-hip ratio (WHR), G) systolic blood pressure 
(SBP, mmHg), and H) diastolic blood pressure (DBP, mmHg), for 11 T2DM patients 
(open circles, placebo; solid circles, CaD; according to per-protocol method). 
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Figure 5: Correlations at 3 years between serum calcidiol (nmol/L) and A) fasting serum 
glucose (FSG, mmol/L), B) fasting serum insulin (pmol/L), C) glycated hemoglobinA 1 c 
(HbA 1 c, % ), D) homeostatic model assessment of insulin resistance (HOMA-IR), E) 
homeostatic model assessment of J3-cell function (HOMA-8), F) triglycerides (TG, 
mmol/L), G) total cholesterol {TC, mmol/L), H) low-density lipoprotein cholesterol (LDL-
C, mmol/L), I) high-density lipoprotein cholesterol (HDL-C, mmol/L), and J) total 
cholesterol/HDL-C ratio (TC/HDL-C, mmol/L), for 11 T2DM patients (open circles, 
placebo; solid circles, CaD; according to per-protocol method). 
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Figure 6: Correlations at 3 years between serum calcidiol (nmol/L) and A) parathyroid 
hormone (PTH, pmol/L), B) aspartate transaminase (AST, U/L), C) alanine 
transaminase (ALT, U/L), D) serum calcium (mmol/L), E) serum albumin (g/L), F) serum 
creatinine (µmol/L), and G) estimated glomerular filtration rate ( eGFR, mUmin/1. 73 m2) 
for 11 T2DM patients (open circles, placebo; solid circles, CaD; according to per-
protocol method). 
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Absolute change in serum calcidiol over 3 years was negatively correlated 
with the absolute change in body weight, BMI, TBF, HC, SBP, and TC/HDL-C, 
PTH, AST (P = 0.005, P = 0.005, P = 0.094, P = 0.004, P = 0.043, P = 0.085, P 
= 0.038, P = 0.066, respectively) and positively correlated with the absolute 
change in WHR (P = 0.014) (Figures 7,8, and 9). A negative trend was observed 
between serum calcidiol and HbA 1 c (P = 0.117), LDL-C (P = 0.156), and a 
positive trend was observed between serum calcidiol and HDL-C (P = 0.148), 
and serum calcium (P = 0.122) (See Table 10 and Figures 7, 8, and 9). 
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Table 10: Spearman's rank coefficient bivariate correlation for the absolute 
change over 3 y in serum calcidiol with the different outcome measures (n = 11 ). 
Body weight (kg) -0.736 0.005 0.010 
BMI (kg/m2) -0.736 0.005 0.010 
Total body fat (kg) 0.173 0.306 0.612 
Body fat(%) -0.428 0.094 0.188 
WC (cm) 0.055 0.437 0.874 
HC (cm) -0.755 0.004 0.007 
WHR 0.655 0.014 0.029 
SBP (mmHg) -0.540 0.043 0.086 
DBP (mmHg) 0.114 0.369 0.736 
FSG (mmol/L) 0.064 0.426 0.852 
Fasting serum insulin (pmol/L) 0.014 0.484 0.968 
HbA1c (%) -0.391 0.117 0.235 
HOMA-IR -0.036 0.458 0.916 
HOMA-8 -0.227 0.251 0.502 
TG (mmol/L) 0.087 0.400 0.800 
TC (mmol/L) -0.036 0.458 0.916 
LDL-C (mmol/L) -0.336 0.156 0.312 
HDL-C (mmol/L) 0.346 0.148 0.296 
TC/HDL-C -0.445 0.085 0.170 
PTH (pmol/L) -0.555 0.038 0.077 
AST (U/L) 0.483 0.066 0.133 
ALT (U/L) -0.009 0.489 0.979 
Serum calcium (mmol/L) 0.384 0.122 0.244 
Serum albumin (g/L) -0.192 0.286 0.572 
Serum creatinine (µmol/L) -0.129 0.353 0. 706 
eGFR (ml/min/1.73 m2) -0.046 0.446 0.892 
BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FSG, fasting serum glucose; 
HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-B, homeostatic model assessment of 13-cell function; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; PTH, 
parathyroid hormone; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, 
estimated glomerular filtration rate. P is significant S 0.10. 
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Figure 7: Correlations between the absolute change fl in serum calcidiol (nmol/L) and 
the absolute change fl in A) body weight (kg), B) body mass index (BMI, kg/m2), C) 
body fat (BF,%), D) waist circumference (WC, cm), E) hip circumference (HC, cm), F) 
waist-to-hip ratio (WHR), G) systolic blood pressure (SBP, mmHg), and H) diastolic 
blood pressure (DBP, mmHg), for 11 T2DM patients (open circles, placebo; solid 
circles, CaD; according to per-protocol method). 
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Figure 8: Correlations between the absolute change fl. in serum calcidiol (nmol/L) and 
the absolute change fl. in A) fasting serum glucose (FSG, mmol/L), 8) fasting serum 
insulin (pmol/L), C) glycated hemoglobinA 1 c (HbA 1 c, % ), D) homeostatic model 
assessment of insulin resistance (HOMA-IR), E) homeostatic model assessment of 13-
cell function (HOMA-8), F) triglycerides (TG, mmol/L), G) total cholesterol (TC, mmol/L), 
H) low-density lipoprotein cholesterol (LDL-C, mmol/L), I) high-density lipoprotein 
cholesterol (HDL-C, mmol/L), and J) total cholesterol/HDL-C ratio {TC/HDL-C, mmol/L), 
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at 3 years for 11 T2DM patients (open circles, placebo; solid circles, CaD; according to 
per-protocol method). 
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Figure 9: Correlations between the absolute change b. in serum calcidiol (nmol/L) and 
the absolute change b. in A) parathyroid hormone {PTH, pmol/L), B) aspartate 
transaminase (AST, U/L), C) alanine transaminase (ALT, U/L), D) serum calcium 
(mmol/L), E) serum albumin (g/L), F) serum creatinine (µmol/L), and G) estimated 
glomerular filtration rate (eGFR, mUmin/1.73 m2) for 11 T2DM patients (open circles, 
placebo; solid circles, CaD; according to per-protocol method). 
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Relative change in serum calcidiol over 3 years was negatively correlated 
with the relative change in body weight, BMI, TBF, HC, TC/HDL-C, and PTH (P 
= 0.005, P = 0.005, P = 0.085, P = 0.013, P = 0.095, and P = 0.014, 
respectively), and positively with WHR and serum calcium (P = 0.008 and P = 
0.059) (See figures 10, 11, and 12). A negative trend was observed between 
serum calcidiol and SBP (P = 0.123). In addition, a positive trend was observed 
between serum calcidiol and DBP (P = 0.123) and HDL-C (P = 0.156) (Table 
11 ). 
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Table 11: Spearman's rank coefficient bivariate correlation for the relative 
change over 3 y in serum calcidiol, with the different outcome measures (n = 
11 ). 
Body weight (kg) -0.736 0.005 0.010 
BMI (kg/m2) -0.736 0.005 0.010 
Total body fat (kg) -0.736 0.005 0.010 
Body fat(%) -0.445 0.085 0.170 
WC (cm) 0.182 0.296 0.592 
HC (cm) -0.664 0.013 0.026 
WHR 0.700 0.008 0.016 
SBP (mmHg) -0.382 0.123 0.246 
DBP (mmHg) 0.164 0.315 0.631 
FSG (mmol/L) 0.109 0.375 0.750 
Fasting serum insulin (pmol/L) 0.064 0.426 0.852 
HbA1c (%) -0.218 0.260 0.520 
HOMA-IR 0.109 0.375 0.750 
HOMA-B -0.009 0.489 0.978 
TG (mmol/L) 0.218 0.260 0.520 
TC (mmol/L) -0.041 0.452 0.904 
LDL-C (mmol/L) -0.064 0.426 0.852 
HDL-C (mmol/L) 0.336 0.156 0.312 
TC/HDL-C -0.427 0.095 0.190 
PTH (pmol/L) -0.655 0.014 0.028 
AST (U/L) 0.318 0.170 0.340 
ALT (U/L) -0.009 0.489 0.978 
Serum calcium (mmol/L) 0.500 0.059 0.118 
Serum albumin (g/L) -0.087 0.400 0.546 
Serum creatinine (µmol/L) -0.045 0.447 0.894 
e-GFR (ml/min/1. 73 m2) -0.145 0.335 0.670 
BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FSG, fasting serum glucose; 
HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-8, homeostatic model assessment of f3-cell function; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; PTH, 
parathyroid hormone; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, 
estimated glomerular filtration rate. Pis significant~ 0.10. 
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Figure 10: Correlations between the relative change(~%) in serum calcidiol (nmol/L) 
and the relative change(~%) in A) body weight (kg), B) body mass index (BMI, kg/m2), 
C) body fat (BF,%), D) waist circumference (WC, cm), E) hip circumference (HC, cm), 
F) waist-to-hip ratio (WHR), G) systolic blood pressure (SBP, mmHg), and H) diastolic 
blood pressure (DBP, mmHg), for 11 T2DM patients (open circles, placebo; solid 
circles, CaD; according to per-protocol method). 
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Figure 11: Correlations between the relative change(~%) in serum calcidiol (nmol/L) 
and the relative change(~%) in A) fasting serum glucose (FSG, mmol/L), B) fasting 
serum insulin (pmol/L), C) glycated hemoglobinA 1c(HbA1 c, % ), D) homeostatic model 
assessment of insulin resistance (HOMA-IR),. E) homeostatic model assessment of~­
cell function (HOMA-B), F) triglycerides {TG, mmol/L), G) total cholesterol {TC, mmol/L), 
H) low-density lipoprotein cholesterol (LDL-C, mmol/L), I) high-density lipoprotein 
cholesterol (HDL-C, mmol/L), and J) total cholesterol/HDL-C ratio {TC/HDL-C, mmol/L), 
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for 11 T2DM patients (open circles, placebo; solid circles, CaD; according to per-
protocol method). 
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Figure 12: Correlations between the relative change (b.%) in serum calcidiol (nmol/L) 
and the relative change (b.%) in A) parathyroid hormone {PTH, pmol/L), 8) aspartate 
transaminase (AST, U/L), C) alanine transaminase (ALT, U/L), D) serum calcium 
(mmol/L), E) serum albumin (g\L), F) serum creatinine (µmol/L), and G) estimated 
glomerular filtration rate (eGFR, mUmin/1.73 m2) for 11 T2DM patients (open circles, 
placebo; solid circles, CaD; according to per-protocol method). 
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Table 12 depicts the results based on the per-protcol, in the Cao group, 
serum calcidiol increased significantly (P = 0.018), while the following measures 
decreased significantly over 3 years total body fat (kg) (P = 0.018), TC (P = 
0.018), LOL-C (P = 0.034 ), TC/HOL (P = 0.091 ), PTH (P = 0.093), AST (P = 
0.018) and serum creatinine (P = 0.041 ), compared to their baseline levels. In 
the placebo group, total body fat decreased significantly (P = 0.068), and HbA 1 c 
increased significantly (P = 0.068), compared to their baseline levels. Moreover, 
after 3 years, Cao group had significantly lower body weight (P = 0.042), BMI (P 
= 0.024), total body fat (P = 0.042), body fat(%) (P = 0.073), HC (P = 0.042), 
and PTH (P = 0.024 ), compared to the placebo group 
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Table 12: Comparison of the medians in outcome measures in participants, both within 
group and between groups, following per-protocol analysis, for T2DM 
Body weight (kg) 91.9 92.6 0.144 73.5 76.0 0.674 0.042 
BMI (kg/m2) 34.7 37.1 0.144 27.7 32.0 0.753 0.024 
Total body fat (kg) 30.9 20.1 0.068 24.7 16.5 0.018 0.042 
Body fat(%) 35.4 44.6 0.144 32.5 38.1 0.866 0.073 
WC (cm) 101.0 104.1 0.465 89.5 96.5 1.000 0.315 
HC (cm) 126.0 121.9 0.465 116.0 108.0 0.176 0.042 
WHR 0.84 0.86 0.581 0.79 0.89 0.108 0.527 
SBP (mmHg) 126.0 135.5 0.144 135.0 137.0 0.498 0.788 
DBP (mmHg) 80.0 77.5 0.465 85.0 91.0 0.310 0.315 
Serum calcidiol (nmol/L) 106.5 79.0 0.581 54.0 66.0 0.018 0.648 
FSG (mmol/L) 7.3 6.9 0.715 7.0 6.4 0.498 0.788 
Fasting serum insulin 67.0 53.5 0.144 65.0 83.0 0.598 1.000 
mol/L 
HbA1C(%) 7.1 7.9 0.068 7.5 7.5 0.672 0.788 
HOMA-IR 21.7 21.3 0.273 20.2 27.8 0.866 1.000 
HOMA-B 384.04 213.0 0.715 178.6 242.4 0.866 1.000 
TG (mmol/L) 0.83 0.82 0.593 1.01 1.14 0.446 0.230 
TC (mmol/L) 3.91 3.25 0.144 5.17 4.58 0.018 0.527 
LDL-C (mmolUL) 2.23 1.48 0.680 3.33 2.25 0.018 0.527 
HDL-C (mmol/L) 1.44 1.41 0.715 1.40 1.40 0.345 1.000 
TC/HDL-C 2.63 2.45 0.144 3.56 2.59 0.091 0.315 
PTH (pmol/L) 7.5 7.5 0.715 5.0 3.7 0.093 0.024 
AST (U/L) 20.5 18.0 0.144 22.0 17.0 0.018 1.000 
ALT (U/L) 15.0 14.0 0.285 21.0 17.0 0.116 0.412 
Serum calcium (mmol/L) 2.4 2.5 0.144 2.4 2.4 0.751 0.164 
Serum albumin (g/L) 43.0 44.5 0.285 41.0 41.0 0.18 0.648 
Serum creatinine 70.5 65.5 0.194 79.0 72.0 0.041 0.527 
mol/L 
eGFR (ml/min/1.73m2) 73.5 78.5 0.273 69.0 73.0 0.667 0.788 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-8, homeostatic model assessment of ~-cell function; 
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
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triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. Pis significant:::; 0.10. P* denotes significance between groups. 
Table 13: Comparison of the medians of the percent change differences in 
outcome measures in participants, following per-protocol analysis. 
Body weight 4.4 0.0 0.412 
BMI 4.4 0.0 0.412 
Total body fat -32.6 -35.4 0.412 
Body fat(%) 28.9 -3.3 0.109 
WC 1.3 7.1 0.927 
HC 0.7 -2.8 0.412 
WHR 1.6 5.2 0.527 
SBP 10.8 1.5 0.315 
DBP -4.4 7.1 0.412 
Serum calcidiol -30.7 27.5 0.109 
FSG -0.9 -9.3 0.648 
Fasting serum 
-44.4 0.0 0.164 insulin 
HbA1C 13.6 4.7 0.527 
HOMA-IR -47.1 -35.6 0.315 
HOMA-B -39.4 25.6 0.230 
TG 0.4 4.1 0.527 
TC -11.3 -21.8 0.230 
LDL-C -11.5 -34.3 0.648 
HDL-C 2.0 0.0 0.648 
TC/HDL-C -13.1 -8.3 1.000 
PTH -5.3 -18.2 0.315 
AST -17.8 -19.0 0.527 
ALT 0.0 -19.0 0.412 
Serum calcium 3.5 -0.8 0.412 
Serum albumin 9.5 4.6 0.527 
Serum creatinine -8.1 -8.9 0.927 
eGFR 6.3 7.3 0.648 
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BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-B, homeostatic model assessment of ~-cell function; 
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. *P is significant S 0.10. 
Table 14 depicts the results based on the retrospective method, 
compared to baseline, the CaD group had a significant decrease in total body fat 
(P = 0.028), TC (P = 0.075), LDL-C (P = 0.028), TC/HDL-C (P = 0.028), PTH (P 
= 0.043), and serum creatinine (P = 0.058), and increase in WHR (P = 0.028), 
and serum calcidiol (P = 0.028), compared to baseline. While the placebo group 
had a significant increase in body weight (P = 0.080), SBP (P = 0.078), and 
HbA 1 c (P = 0.068), and a significant decrease in total body fat (P = 0.043), TC 
(P = 0.068), AST (P = 0.066), and serum creatinine (P = 0.068). After 3 years, 
subjects who were assigned to the CaD group, had significantly lower body 
weight (P = 0.017), BMI (P = 0.004), total body fat (P = 0.017), body fat(%) (P = 
0.052), WC (P = 0.082), HC (P = 0.030), and PTH (P = 0.030), compared to the 
placebo group. Retrospective analysis also showed differences between the 
CaD vs. placebo in hip circumference (-3.3% vs. +0.3%, respectively, P = 
0.052), serum calcidiol ( +41. 7% vs. -30.3%, respectively, P = 0.004 ), serum PTH 
(-30.8% vs. -3.1 %, respectively, P = 0.003), systolic blood pressure (-1.5% vs. 
+12.0%, respectively, P = 0.126) (Table 15). 
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Body weight (kg) 90.8 95.0 0.080 73.0 74.5 0.893 0.017 
BMI (kg/m2) 35.5 37.1 0.655 27.1 29.7 0.893 0.004 
Total body fat (kg) 30.5 20.6 0.043 24.5 16.2 0.028 0.017 
Body fat(%) 39.3 44.1 0.180 32.3 34.6 0.893 0.052 
WC (cm) 109.0 104.0 0.180 89.3 92.7 0.600 0.082 
HC (cm) 123.5 121.9 0.893 112.5 107.0 0.173 0.030 
WHR 0.92 0.86 0.225 0.78 0.87 0.028 0.792 
SBP (mmHg) 124.0 136.0 0.078 132.5 129.5 0.752 0.662 
DBP (mmHg) 80.0 74.0 0.343 82.5 91.0 0.173 0.429 
Serum calcidiol 94.0 69.0 0.465 56.5 77.0 0.028 0.429 
nmol/L 
FSG (mmol/L) 7.4 6.8 0.144 6.8 6.4 0.752 0.792 
Fasting insulin 86.0 100.0 0.357 48.5 44.5 0.416 0.126 
mol/L 
HbA1C(%) 6.9 7.5 0.068 7.9 8.2 0.833 0.662 
HOMA-IR 27.5 27.8 0.500 13.3 9.2 0.463 0.247 
HOMA-8 464.9 606.1 0.500 173.3 187.2 0.345 0.082 
TG (mmol/L) 0.87 0.90 1.000 1.00 1.08 0.293 0.792 
TC (mmol/L) 3.93 2.67 0.068 5.44 4.85 0.075 0.052 
LDL-C (mmolUL) 2.05 1.05 0.109 3.48 2.43 0.028 0.177 
HDL-C (mmol/L) 1.43 1.29 0.465 1.42 1.50 0.893 0.126 
TC/HDL-C 3.22 2.20 0.715 3.82 2.75 0.028 0.329 
PTH (pmol/L) 6.5 6.3 0.465 6.1 3.8 0.043 0.030 
AST (U/L) 23.0 18.0 0.066 21.5 17.5 0.115 1.000 
ALT (U/L) 22.0 17.0 1.000 19.0 16.0 0.144 1.000 
Serum calcium 2.4 2.5 0.581 2.3 2.4 0.141 0.429 
mmol/L 
Serum albumin (g/L) 40.0 44.0 0.180 43.0 43.5 0.581 1.000 
Serum creatinine 76.0 70.0 0.068 75.5 70.5 0.058 1.000 
mol/L 
eGFR 69.0 71.0 0.102 73.0 74.0 0.140 0.662 
ml/min/1. 73m2 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-B, homeostatic model assessment of ~-cell function; 
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TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. P is significant S 0.10. P* denotes significance between groups. 
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Table 15: Comparison of the medians of the percent change differences in 
outcome measures in participants, following retrospective analysis. 
Body weight 4.2 -0.4 0.247 
BMI 4.2 -0.4 0.247 
Total body fat -32.7 -35.7 0.247 
Body fat(%) 11.7 -1.1 0.429 
WC -2.0 7.5 0.247 
HC 0.3 -3.3 0.052 
WHR -2.52 8.49 0.004 
SBP 12.0 1.5 0.126 
DBP -11.3 4.1 0.329 
Serum calcidiol -30.3 41.7 0.004 
FSG -9.3 -6.6 0.931 
Fasting serum insulin -24.5 -20.1 1.000 
HbA1C 4.7 -0.8 0.329 
HOMA-IR -35.6 -46.6 1.000 
HOMA-8 8.4 12.8 1.000 
TG 0.9 3.1 0.931 
TC -16.7 -19.3 1.000 
LDL-C -15.3 -26.7 1.000 
HDL-C -2.8 0.5 0.792 
TC/HDL-C -11.8 -13.9 0.537 
PTH -3.1 -30.8 0.030 
AST (U/L) -18.2 -13.1 0.662 
ALT (U/L) 0.0 -9.5 0.537 
Serum calcium -0.4 3.8 0.429 
Serum albumin 9.5 4.5 0.429 
Serum creatinine -6.3 -10.2 0.792 
eGFR 7.3 7.4 0.931 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA 1 C, glycated hemoglobin A 1 c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-B, homeostatic model assessment of 13-cell function; 
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
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cholesterol; TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. *P is significant S 0.10. 
Diet intake was assessed by 3-day (2 weekdays and 1 weekend) diet 
record at baseline and at the 3-year follow-up. Mean intake of the macro- and 
micro- nutrients is summarized in Table 16. Vitamin D and calcium intake 
through the diet were lower than the recommended daily allowance (600 IU/d 
and 1200 mg, respectively). 
Table 16: Macronutrients intake at baseline and at 3 years for all T2DM patients 
(n =11 ), presented as means ± SD. 
Energy (Kcal) 1458 ± 578 1394 ± 522 
Carbohydrates (g) 228 ± 123 210±110 
Total protein (g) 63±14 37±13 
Total fat (g) 36±14 62±15 
Saturated fat (g) 9±4 10 ± 4 
Monounsaturated 12 ± 5 12 ± 4 
Polyunsaturated 8±4 8±4 
Cholesterol (mg) 279 ± 301 296 ± 330 
Vitamin D (IU) 91.0 ± 48.8 101.0 ± 47.9 
Calcium (mg) 492 ± 264 537 ± 264 
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12. Discussion 
This clinical trial investigated the effect of vitamin 0 3 and calcium 
supplementation on glycemic control and other sequelae in type 2 diabetic 
patients from multi-ethnic background. In the present study, absolute and 
relative change in serum calcidiol (vitamin D status) negatively correlated with 
the absolute and relative change in body weight and BMI, total body fat (only in 
the relative change), body fat(%), HC, SBP, TC/HDL-C, PTH, and positively 
correlated with absolute and relative change in WHR and serum calcium (only in 
the relative change). At 3 years, there was a negative correlation between serum 
calcidiol and DBP and HbA 1 C. When the data were analyzed using the per-
protocol method was used, the CaD group had a significant increase in serum 
calcidiol, and decrease in TC, LDL-C, TC/HDL, PTH, AST, and serum creatinine, 
compared to baseline values. However, when the data were analyzed using the 
retrospective method, the CaD group had a significant increase in WHR and 
serum calcidiol, and decrease in total body fat, TC, LDL-C, TC/HDL-C, PTH, and 
serum creatinine, compared to baseline values. 
Serum calcidiol was measured in all participants during the summer 
months (May-June) at baseline and after 3 years. Although, median serum 
calcidiol levels increased significantly in the CaD group by 27%, it did not reach 
optimal levels (> 75 nmol/L) (72,88) when analyzed using per-protocol, likely due 
to poor compliance and poor adherence to the study protocol. However, when 
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using the retrospective method, all subjects had serum calcidiol levels> 50 
nmol/L, that accounted for a modest 41 % increase, reaching an average of 77 
nmol/L, a value considered optimal according to the IOM (71 ). Additionally, the 
retrospective method showed differences between the CaD vs. placebo in serum 
calcidiol (+41.7% vs. -30.3%, respectively, P = 0.004). The poor compliance 
could be attributed to participants requiring consuming 4 pills per day combined 
with quite lengthy study duration. Dietary vitamin D intake was assessed by 3-
day food record; mean vitamin D intake at baseline (90 IU/d) and at 3 years (101 
IU/d) does not meet vitamin DRDA (600 IU/d) (54). In another human clinical 
trial, the consumption of 2000 IU/d D3 for 12 weeks, allowed for optimal (> 75 
nmol/L) serum calcidiol levels in Black youth who had baseline levels of 33.1 
nmol/L (101 ). Moreover, 1000 IU/d of vitamin D3 and calcium fortified yogurt 
increased serum calcidiol levels to > 70 nmol/L from baseline values of 44 
nmol/L, after 12 weeks in Middle-Eastern diabetic patients (age 50.7 ± 6.1 y) 
(111 ). However, diabetic patients who had serum calcidiol baseline levels of 29 
nmol/L and were supplemented with the same 1000 IU/d dose for 12 months did 
not achieve optimal levels ( 43.8 nmol/L); authors reported a large number of 
drop-outs (158). In Black youth, daily consumption of 2000 IU D3 increased 
serum calcidiol levels from 33.1 to 86 nmol/L after 16 weeks (90). Finally, in 
clinical trials that used the current upper tolerable intake ( 4000 I U/D3), serum 
calcidiol levels consistently reached optimal levels after 12 weeks (144, 148, 159) 
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or 16 weeks (160). Findings of the present study confirm the need to revise the 
vitamin D recommended daily allowance while considering ethnicity and health 
conditions. 
Serum calcidiol and body composition 
The change in serum calcidiol (absolute and relative vs. baseline) 
negatively correlated with body weight, BMI, body fat(%), and HC. These 
findings are consistent with those of Nikooyeh et al, in which changes in serum 
calcidiol negatively correlated with weight (r = -0.331, P = 0.001 ), BMI (r = -
0.358, P = 0.001 ), and fat mass (r = -0.219, P = 0.038) (93, 111 ). Moreover, 
absolute and relative change in serum calcidiol levels negatively correlated with 
PTH, as corroborated by previous studies (85,89, 161, 162). The beneficial effect 
of vitamin D on adiposity could be explained by its effect on PTH and, therefore, 
serum calcium (108). High intracellular Ca2+ concentrations promote lipogenesis 
and, consequently, weight gain (108,163,164). In a population-based study, 
serum calcidiol was inversely associated with BMI, TBF%, and WC 
(standardized J3-values -0.096, -0.194, and -0.109, P < 0.05; respectively); with 
these variables being positively associated with PTH (standardized J3-values 
0.126, 0.214, and 0.071 P < 0.005, respectively) (100). In the Framingham Heart 
study, vitamin D deficiency ( < 49.8 nmol/L) was higher among those who had a 
BMI of;::: 30 kg/m2, and serum calcidiol concentration was inversely associated 
with WC and BMI (regression coefficient [SE] -3.11, P < 0.0001 and -2.81, P < 
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0.0001, respectively) after adjustment for age, sex, and season (165). Vitamin D 
is a fat soluble vitamin which is stored in the body fat compartments, which 
explains the association between low circulating calcidiol concentrations and 
increased fat mass (180). The positive correlation observed between serum 
calcidiol and WHR in the current analysis is an artifact due to a significant 
negative correlation with HC, but not WC. 
In both analyses (per-protocol and retrospective), those who were in the 
CaD group had significantly lower body weight, BMI, total body fat, and body fat 
(% ), WC (only in retrospective), and HC after 3 years as compared to the 
placebo group. The observed non-significant increase in BMI in the CaD group, 
compared to baseline, is due to the increase in body weight not body fat; hence, 
the significant decrease in total body fat indicates that subjects in the CaD group 
became leaner by 36% (retrospective). Vitamin 0 3 and calcium supplementation 
attenuated the increase in HC (retrospective: -3.25% vs +0.32%, P = 0.052), 
body weight and other body composition measures (body weight, BMI, body fat 
(%)). 
Absolute change in serum calcidiol negatively correlated with the absolute 
change in SBP. At 3 years, serum calcidiol negatively correlated with DBP. 
Hypertension is highly prevalent in diabetic patients, and contributes to 
increased risk of cardiovascular disease (166). These findings further support 
the hypothesis that vitamin D is a negative regulator of the renin-angiotensin 
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system, generated from animal model studies (167). In vivo, VDR knock-out 
mice exhibit significant increases in SBP and DBP compared to wild type (== 29% 
and 27%, respectively) ( 167). This is also in agreement with a cross-sectional 
study which found serum calcitriol to be inversely correlated with DBP (r = -0.41) 
in healthy, middle-aged men (mean age 63 y) (168). However, results from 
human clinical trials are inconclusive and equivocal. In one of the largest human 
clinical trials, vitamin 03 and calcium supplementation ( 400 I U D3'd and 1000 mg 
of elemental calcium) did not affect SBP or DBP in multi-ethnic postmenopausal 
women (169), perhaps due to the low amount of supplemental vitamin 0 3. 
Another randomized clinical trial investigated the effect of 5000 I U D3'd for 12 
weeks on endothelial function in 50 diabetic patients (170). After 12 weeks, 5000 
IU of vitamin 0 3 did not affect SBP or DBP (170). In the current study, subjects 
who were in the placebo group had significantly higher SBP by 12% after 3 
years compared to baseline values, according to retrospective analysis. 
Additionally, vitamin 03 supplementation attenuated the increase in SBP in CaD 
vs placebo (retrospective: +1 % vs +12, respectively, P = 0.126) 
Moreover, PTH decreased significantly in the CaD by 31 % after 3 years 
compared to baseline values, according to retrospective analysis, (vs. -3% in the 
placebo group). 
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Serum calcidiol and glycemic biomarkers 
The correlation between serum calcidiol levels and glycemic control 
biomarkers (FSG, fasting serum insulin, HbA 1 c, and HOMA-IR) was investigated 
in the current study. At 3 years, a negative trend in the correlation between 
serum calcidiol and fasting serum glucose was detected. Serum calcidiol 
negatively correlated with fasting plasma glucose (r = -0.28, P = 0.02) after 
adjusting foJ BMI and race in cross-sectional study in obese female adolescents 
(132) and in another clinical trial that supplemented 1000 IU/d 0 3 to diabetic 
patients (Middle-eastern, age 50. 7 ± 6.1 y) for 12 weeks (r = -0.208, P = 0.049) 
(111 ). Vitamin D's role in controlling glycemia is based on its ability to enhance 
insulin sensitivity through the facilitation of glucose uptake in adipose tissue 
(171) and muscle (172), both tissues possess the VDR. Therefore, vitamin D 
stimulates insulin receptor transcription and insulin signaling pathways in these 
tissues, ultimately lowering blood glucose levels (173). Moreover, VDR presence 
in pancreatic ~-cells facilitates insulin production and secretion (150). Indeed, 
supplementing South Asian, vitamin D deficient women (mean age 41.5 y) with 
4000 IU 03/d for 6 months increased serum calcidiol from baseline values of 21 
nmol/L to > 80 nmol/L, improving insulin sensitivity by 41 %(86). Vitamin D 
repletion (from 26.3 nmol/L to 63 nmol/L) improved fasting serum glucose in a 
subgroup of vitamin D deficient, obese, female adolescents by 5.2% (132). 
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Fasting serum insulin positively correlated (non-significantly) with serum 
calcidiol levels in the current analysis (at baseline, r = 0.255; at 3 years, r = 
0.036; absolute change, r = 0.014; and relative change, r = 0.064). However, in a 
cross-sectional study, fasting insulin negatively correlated with serum calcidiol (r 
= -0.42, P = 0.03) after adjusting for BMI in Caucasian Americans, but not in 
African Americans ( 132). Another multi-ethnic, cross-sectional study also 
indicated inverse adjusted association of serum calcidiol and fasting insulin (P = 
0.019) (85). There are several possible explanations for these results. For 
example, in the former study ( 132), mean baseline fasting insulin levels were 
relatively higher than in our participants at baseline (232 pmol/L vs 132 pmol/L in 
our study), and in the latter (85), the association was derived from multi-ethnic 
population, including whites, Hispanics and others. Most importantly, FSG 
positively correlated with serum calcidiol in our analysis for both the absolute 
and relative change from baseline, which would explain the positive correlation 
with fasting insulin. 
Our study also showed that serum calcidiol levels are negatively 
correlated with HbA 1 c at 3 years. In addition, a negative trend between serum 
calcidiol and HbA 1 c at baseline and the absolute change from baseline was 
observed. This negative correlation was observed in another cross-sectional 
study, in which serum calcidiol levels were inversely associated with HbA 1 c (r2 = 
0.058, P = 0.008) in diabetic patients and non-diabetic controls (r2 = 0.086, P = 
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0.001) (174). In a human clinical trial, HbA 1 c significantly decreased by 6.4% in 
diabetic patients after 12 weeks of vitamin 03 and calcium fortified yogurt (1000 
IU/d 0 3 and 500 mg Ca) (111 ). In the current study, HbA1 c increased 
significantly in the placebo group by 5% compared to baseline values, according 
to retrospective analysis. Vitamin 0 3 supplementation attenuated the increase in 
HbA1c in Cao vs placebo (per protocol: -0.8% vs 5%). 
Finally, in the current study, correlations between serum calcidiol and 
HOMA indices (HOMA-IR and HOMA-8) were negative (but not significant) at 3 
years and when the absolute change from baseline was calculated. One 
unanticipated finding in the current study was the significant increase in HOMA-
8 in the Cao group when using retrospective analysis and the decrease in 
HOMA-IR in the placebo group when using per-protocol analysis. Vitamin 0 3 and 
calcium supplementation did not improve insulin resistance and J3-cell function in 
this sample of diabetic patients. Another clinical trial in pre-diabetic, obese 
African Americans whereby the treatment group (4000 03 IU/d) exhibited 
decreased insulin sensitivity (measured by Mastuda Insulin Sensitivity Index 
MISI) in contrast to a significant increase in insulin sensitivity for the placebo 
group (148). However, improvements in HOMA-IR and HOMA-%S indices by 
11. 7% and 13.3% were observed when serum calcidiol levels reached 80-119 
nmol/L (86, 175). These findings further support the potential role of vitamin 0 in 
attenuating glycemic biomarkers in diabetic patients. 
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Serum calcidiol and lipid profile 
The change in serum calcidiol (absolute and relative vs. baseline) 
negatively correlated with TC/HDL-C. Moreover, at baseline, serum calcidiol 
levels negatively correlated with TG, TC, LDL-C, and TC/HDL-C. A positive trend 
was observed in the correlation between serum calcidiol and HDL-C with regard 
to both the absolute and relative change from baseline. Subjects who were in the 
CaD group (for both intent-to treat and retrospective analysis) experienced a 
significant decrease in TC, LDL-C, and TC/HDL-C, compared to baseline. In a 
weight reduction intervention, vitamin 03 supplementation (400 IU/d) for 15 
weeks, was associated with a 13% decrease in LDL-C (145), but not in diabetic 
patients who received 1000 I U/d for 12 months ( 158 ). The positive correlation 
between serum calcidiol and HDL-C in the current study is in agreement with 
previous studies (85, 131, 145, 176), as is the negative correlation with TG (85). 
Moreover, in a 12-week clinical trial intervention that determined the effect of 
high dose of vitamin 0 3 supplementation (5000 IU/d) on endothelial function in 
diabetic patients, serum TG significantly decreased by 8.1 % (170). Vitamin D's 
beneficial effect on lipid profile in diabetic patients might be explained through its 
role in suppressing foam cell formation (109, 110). 
Serum calcidiol and other biomarkers 
Serum calcidiol positively correlated with serum calcium at 3 years and 
with its relative change from baseline. It is worth noting that participants in our 
85 
study were not diagnosed with liver or kidney disease, hence AST, ALT, serum 
creatinine, serum albumin, serum calcium, and eGFR, were within normal 
ranges throughout the study. This was despite the significant decrease in AST in 
the CaD group, and the positive correlation between AST and serum calcidiol. 
Lower serum calcidiol (175) and calcitriol (177) concentrations were observed 
concurrently with very low eGFR (15-29 mL/min/1. 73 m2) as part of stage 4 
chronic kidney disease. Similarly, the negative correlation between serum 
calcidiol and eGFR in the current study, is in agreement with another Canadian 
cross-sectional study that investigated the association between serum calcidiol 
and Mets components (85). 
13.0 Summary and conclusion 
Insulin resistance and elevated fasting serum glucose are fundamental 
aspects in T2DM; evidence suggests a potential role for vitamin D in controlling 
glycemia and attenuating T2DM. Vitamin D deficiency and T2DM share similar 
risk factors such as: non-white ethnicity (21,84,87), obesity (8, 10, 19,20,90, 165), 
and increased age (84,94,95). In addition, seasonal variations influence vitamin 
D status (89-92). Vitamin D deficiency is associated with poor glucose tolerance 
and reduced insulin secretion. This association is based on the fact that VDR, 
which is necessary for vitamin D action, is located in pancreatic J3-cells 
(responsible for insulin secretion) and peripheral tissues (responsible for insulin 
sensitivity). Cross-sectional and prospective studies have shown that low serum 
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calcidiol levels were associated with increased risk of diabetes 
(83,84, 134, 135, 141 ), metabolic syndrome (85, 131, 132, 138), insulin resistance 
and glucose intolerance (129, 130, 136, 137, 139), increased mortality (81,82, 133), 
and increased adiposity (100, 165). In clinical trials that provided a higher dose 
than the RDA (600 IU/d) in diabetics, pre-diabetics, or subjects at high risk of 
T2DM, including a wide range of ethnicities, and combined or not with Ca 
supplementation, favourable effects were observed on glycemic biomarkers 
(86, 111, 144, 148, 149), lipid profile (146), and body composition (111 ). However, 
clinical trials that supplemented relatively lower vitamin D3 (< 800 IU/d) showed 
no effect of vitamin D3 supplementation on T2DM outcomes (178). . 
This pilot study demonstrates that vitamin D3 supplementation may 
attenuate T2DM severity in postmenopausal women of multi-ethnic backgrounds 
even in with modest increases in serum calcidiol level. We suggest a revision of 
the current vitamin D RDA with particular consideration for diverse ethnicities 
and different health conditions. We have also confirmed the negative association 
between serum calcidiol and adiposity, PTH, and LDL-C. Nevertheless, findings 
of this study are weakened due to poor compliance. Further research is indeed 
warranted to produce more robust results as well as investigate the underlying 
mechanisms of vitamin D action in diabetes control. 
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14. Significance of research 
Despite the limitations, the current clinical intervention indeed suggests that 
a modest increase in serum calcidiol mitigates diabetes outcomes and provides 
us with some insight into the potential role of vitamin D3 and calcium 
supplementation in attenuating diabetes severity. Our participant sample was 
relatively small, however it included individuals from three different ethnic groups 
(Caribbean, South Asian, and BlackBlack) that reside in Toronto, Ontario. The 
results of this study serve as the basis for other larger clinical trials to further 
elucidate the role of vitamin D supplementation in mitigating T2DM 
Although the Institute of Medicine (IOM) concluded its revision of the vitamin 
D RDA in 2010, the current study suggests that the committee should reconsider 
the benefit that could be derived from vitamin D supplementation in those 
suffering vitamin D-related diseases such as T2DM. 
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Appendix A 
Presentation of data as means ± SD with parametric tests. 
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Table 17: Baseline characteristics presented as means± SD following per-
protocol assignment, for T2DM subjects (n = 11 ). 
Age (y) 61 ± 10 63 ± 12 59±10 
Body weight (kg) 79.3 ± 15.5 90.0 ± 6.7 73.3 ± 16.2 
BMI (kg/m2) 31.4 ± 5.3 35.0±1.5 29.4 ± 5.8 
Total Body fat (kg) 26.7 ± 5.2 30.2 ± 2.3 24.6 ± 5.4 
Body fat(%) 34.3 ± 7.5 35.6 ± 6.7 33.6 ± 8.3 
WC (cm) 95.0 ± 13.2 99.8 ± 9.3 92.4 ± 15.0 
HC (cm) 114.2 ± 14.2 119.6±17.4 111.1 ± 12.4 
WHR 0.83 ± 0.08 0.84 ± 0.08 0.83 ± 0.08 
SBP (mmHg) 129.5 ± 13.2 130.0 ± 14.0 129.3 ± 14.0 
DBP (mmHg) 82.2 ± 5.8 81.0±3.5 82.9 ± 7.0 
Serum Calcidiol (nmol/L) 73.2 ± 31.7 109.0 ± 15.8 52.7 ± 14.3 
FSG (mmol/L) 7.5 ± 2.1 7.7±1.2 7.4 ±2.6 
Fasting insulin (pmol/L) 132.6 ± 201.5 225.3 ± 330.3 79.7 ± 64.5 
HbA1C (%) 7.7±1.3 7.2 ± 0.7 8.0±1.6 
HOMA-IR 47.7 ± 85.4 89.5 ± 141.0 23.8 ± 19.9 
HOMA-B 553 ± 708 864 ± 1055 376 ± 422 
TG (mmol/L) 1.01 ± 0.32 0.87 ± 0.20 1.10 ± 0.35 
TC (mmol/L) 4.76±1.18 3.94 ± 1.18 5.23 ± 0.95 
LDL-C (mmol/L) 2.82 ± 0.99 2.24 ± 1.25 3.16 ± 0.69 
HDL-C (mmol/L) 1.53 ± 0.46 1.45 ± 0.11 1.58 ± 0.58 
TC/HDL-C (mmol/L) 3.22 ± 0.84 2.71 ± 0.82 3.51 ± 0.76 
PTH (pmol/L) 6.5 ± 2.2 7.7±'1.3 5.8 ±2.3 
AST (U/L) 26.4 ± 16.1 20.0 ± 3.16 30.1±19.6 
ALT (U/L) 26.8 ± 24.6 16.3 ± 3.9 32.9 ± 29.7 
Serum Calcium (mmol/L) 2.4 ± 0.1 2.4 ± 0.1 2.4±0.1 
Serum albumin (g/L) 41.8 ± 3.6 42.5 ± 3.4 41.4 ± 3.8 
Serum Creatinine 77.6 ± 10.3 78.0 ± 16.8 77.4 ± 6.1 (µmol/L 
eGFR (ml/min/1.73m2) 70.5±11.1 71.0 ± 17.2 70.1±7.6 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; FSG, fasting 
serum glucose; HbA 1 C, glycated hemoglobin A 1 c; HOMA-IR, homeostatic model assessment of 
insulin resistance; HOMA-8, homeostatic model assessment of ~-cell function; LDL-C, low-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol, TC/HDL-C, 
total cholesterol and high-density lipoprotein cholesterol ratio; TG; triglycerides; AST, aspartate 
transaminase; ALT, alanine transaminase; and eGFR, estimated glomerular filtration rate. 
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Table 18: Baseline characteristics presented as means ± SD following 
retrospective assignment, for T2DM subjects (n = 11). 
Body weight (kg) 90.0 ± 7.5 70.5 ± 15.2 
BMI (kg/m2) 35.6 ± 1.3 28.0 ± 5.0 
Total body fat (kg) 30.2 ± 2.5 23.7 ± 5.1 
Body fat(%) 37.5 ± 7.3 31.7 ± 7.2 
WC (cm) 103.4 ± 10.6 88.1 ± 11.5 
HC (cm) 117.6 ± 13.6 111.4 ± 15.3 
WHR 0.88 ± 0.07 0.79 ± 0.06 
SBP (mmHg) 129.4 ± 15.0 129.7 ± 13.1 
DBP (mmHg) 82.8 ± 5.0 81.7 ± 6.8 
Serum calcidiol (nmol/L) 87.6 ± 30.8 61.2 ± 29.5 
FSG (mmol/L) 7.7 ± 1.0 7.4 ± 2.9 
Fasting serum insulin (pmol/L) 212.4 ± 286.0 66.2 ±64.3 
HbA1C (%) 6.9 ± 0.4 8.4 ± 1.5 
HOMA-IR 81.8 ± 122.9 19.3 ± 19.8 
HOMA-B 869 ± 911 290 ± 397 
TG (mmol/L) 1.03 ± 0.39 1.00 ± 0.28 
TC (mmol/L) 3.92 ± 1.00 5.46 ± 0.82 
LDL-C (mmol/L) 2.18 ± 1.06 3.36 ± 0.54 
HDL-C (mmol/L) 1.39 ± 0.17 1.65 ± 0.60 
TC/HDL-C 2.86 ± 0.78 3.52 ± 0.83 
PTH (pmol/L) 6.6 ± 2.2 6.4 ± 2.4 
AST (U/L) 24.6 ±4.7 28.0 ±22.3 
ALT (U/L) 22.0 ± 9.8 30.8 ± 33.0 
Serum calcium (mmol/L) 2.4 ± 0.1 2.3 ± 0.1 
Serum albumin (g/L) 41.2 ± 3.7 42.3 ± 3.7 
Serum creatinine (µmol/L) 79.2 ± 14.2 76.3 ± 6.9 
eGFR (ml/min/1. 73m2) 68.2 ± 14.6 72.3 ± 8.2 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; FSG, fasting serum glucose; HbA 1 C, glycated 
hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-8, homeostatic model 
assessment of f3-cell function; LDL-C! low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, 
total cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; triglycerides; AST, 
aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated glomerular filtration rate. 
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Table 19: subjects characteristics at 3 y, presented as means ± SD, following 
per-protocol assignment, for T2DM subjects (n = 11 ). 
Body weight (kg) 93.2 ± 5:2 74.8 ± 16.9 
BMI (kg/m2) 36.4 ± 2.5 29.9 ± 5.6 
Total body fat (kg) 20.2 ± 1.1 16.2 ± 3.7 
Body fat(%) 44.3 ± 1.7 43.4 ± 10.1 
WC (cm) 104.7 ± 3.7 88.0 ± 25.0 
HC (cm) 122.5 ± 5.6 108.8 ± 11.7 
WHR 0.86 ± 0.06 0.89 ± 0.06 
SBP (mmHg) 140.3 ± 19.6 131.3 ± 19.5 
DBP (mmHg) 77.8 ± 10.2 83.6 ± 12.8 
Serum calcidiol (nmol/L) 91.5 ± 51.7 70.1 ± 16.7 
FSG (mmol/L) 7.0 ±·2.9 6.6 ± 2.3 
Fasting serum insulin (pmol/L) 121.3 ± 157.9 71.6 ± 39.0 
HbA1C (%) 8.0 ± 0.7 8.1 ± 1.5 
HOMA-IR 26.4 ±22.0 21.6 ± 14.4 
HOMA-B 17994 ± 35604 173 ± 857 
TG (mmol/L) 0.88 ± 0.19 1.09 ± 0.31 
TC (mmol/L) 3.60 ± 1.30 4.22 ± 1.2 
LDL-C (mmol/L) 1.78 ± 1.01 2.25 ± 1.01 
HDL-C (mmol/L) 1.47 ± 0.25 1.47 ± 0.42 
TC/HDL-C 2.40 ± 0.52 2.92 ± 0.72 
PTH (pmol/L) 7.8 ± 2.8 4.2 ± 0.9 
AST (U/L) 17.0 ± 2.7 18.6 ± 7.1 
ALT (U/L) 16.0 ±4.8 19.0 ± 8.6 
Serum calcium (mmol/L) 2.5 ± 0.1 2.4 ± 0.1 
Serum albumin (g/L) 44.8 ± 1.0 43.3 ± 3.6 
Serum creatinine (µmol/L) 72.5 ± 20.4 71.7 ± 7.5 
eGFR (ml/min/1. 73m2) 75.5 ±22.8 73.0 ± 18.1 
BMI; body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; FSG, fasting serum glucose; HbA1C, 
glycated hemoglobin A 1 c; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-B, homeostatic 
model assessment of ~-cell function; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; TC, total cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated glomerular filtration 
rate. 
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Table 20: Subject characteristics at 3 y, presented as means ± SD, following 
retrospective assignment, for T2DM subjects (n = 11 ). 
Body weight 93.2 ± 6.7 71.7 ± 15.5 
BMI· (kg/m ) 36.9 ±· 1.2 28.4 ± 4.7 
Total body fat (kg) 20.2 ± 1.5 15.5 ± 3.6 
Body fat(%) 44.0 ± 1.9 33.0 ± 10.2 
WC (cm) 105.0 ± 2.8 84.9 ± 25.9 
Hq (cm) 121.9 ± 5.4 101.1 · ± 11.7 
WHR 0.'86 ± 0.05 0.89 ± 0.06 
SBP (mmHg) 141.2 ± 22.9 129.0 ± 15.1 
DBP(mmHg) 77.6 ± 8.3 84.7 ± 13.9 
Serum calcidiol (nmol/L) 65.0 ± 18.2 88.7 ±40.0 
FSG (mmol/L) 6.8 ± 2.5 6.6 ± 2.5 
Fasting serum insulin (pmol/L) 134.4 ± 127.0 . 52.3 ± 38.3 
HbA1C (%) 7.8 ± 0.9 8.3 ± 1.5 
HOMA-IR 31.6 ± 15.1 16.5 ± 15.6 
HOMA-B 14674 ± 31712 -30 ± 823 
TG (mm61/L) 0.97 ± 0.23 1.05 ± 0.34 
TC (mmol/L) 3.32 ± 1.10 4.55 ± 1.06 
LDL-C (mmol/L) 1.62 ± 0.95 2.46 ± 0.91 
HDL-C (mmol/L) 1.30 ± 0.10 1.61 ± 0.43 
TC/HDL-C 2.56 ± 0.8 2.88 ± 0.57 
PTH (pmol/L) 7.2 ± 2.9 4.1 ± 0.8 
AST (U/L) 17.6 ± 5.0 18.3 ± 6.7 
ALT (U/L) 17.8 ± 5.0 18.0 ± 9.3 
Serum calcium (mmol/L) 2.4 ± 0.1 2.4 ± 0.1 
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Serum albumin (g/L) 44.2 ± 2.2 43.5 ± 3.6 
Serum creatinine (µmol/L) 74.2 ± 16.9 70.2 ± 9.0 
eGFR (ml/min/1.73m2) 72.0 ± 18.8 75.5 ± 10.1 
BMI; body mass index; WC, w~ist circumference; HC, hip circumference; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; 
FSG, fasting serum glucose; HbA1C, glycated hemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HOMA-8, homeostatic model assessment of ~-cell function; 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total 
cholesterol, TC/HDL-C, total cholesterol and high-density lipoprotein cholesterol ratio; TG; 
triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; and eGFR, estimated 
glomerular filtration rate. 
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Table 21: Comparison of outcome measures, presented as means ± SD, in 
participants within-group, following retrospective assignment, for T2DM 
subjects (n = 11 ). · · 
Body weight 90.0 ± 7.5 93.2 ± 6.7 0.086 70.5 ± 15.2 71.7 ± 15.5 
BMI (kg/m ) 35.6 ± 1.3 36.9 ± 1.2 0.095 28.0 ± 5.0 28.4 ± 4.7 
Total body fat < 
30.2 ± 2.5 20.2 ± 1.5 23.7 ± 5.1 15.5 ± 3.4 (kg) 0.005 
Body fat(%) 37.5 ± 7.3 44.0 ± 1.9 0.167 31.7 ± 7.2 33.0 ± 10.2 
WC (cm) 103.4 ± 10.6 105 ± 2.8 0.776 88.1 ± 11.5 84.9 ± 25.9 
HC (cm) 117.6 ± 13.6 121.9 ± 5.4 0.411 111.4 ± 15.3 107.1 ± 11.7 
WHR 0.88 ± 0.07 0.86 ± 0.05 0.287 0.79 ± 0.06 0.89 ± 0.06 
SBP (mmHg) 129.4 ± 15.0 141.2 ± 22.9 0.062 129.7 ± 13.1 129.0 ± 15.1 
DBP (mmHg) 82.8 ± 5.0 77.6 ± 8.3 0.390 81.7 ± 6.8 84.7 ± 13.9 
Serum 
calcidiol 87.6 ± 30.8 65.0 ± 18.2 0.112 61.2 ± 29.5 88.7 ±40.0 
(nmol/L) 
FSG (mmol/L) 7.7 ± 1.0 6.8 ± 2.5 0.258 7.4 ± 2.9 6.6 ± 2.5 
Fasting serum 
insulin 212.4 ± 286.0 134.4 ± 127.0 0.342 66.2 ± 64.3 52.3 ± 38.3 
(pmol/L) 
HbA1C (%) 6.9 ± 0.4 7.8 ± 0.9 0.103 8.4 ± 1.5 8.3 ± 1.49 
HOMA-IR 81.8 ± 122.9 31.6 ± 15.1 0.360 19.3 ± 19.8 16.4 ± 15.6 
HOMA-B 869 ± 911 14674 ± 31712 0.373 290 ± 397 -30 ± 823 
TG (mmol/L) 1.03 ± 0.39 0.97 ± 0.23 0.772 1.00 ± 0.28 1.05 ± 0.34 
TC (mmol/L) 3.92 ± 1.00 3.32 ± 1.10 0.060 5.46 ± 0.82 4.55 ± 1.06 
LDL-C 
2.·18 ± 1.06 1.62 ± 0.95 0.098 3.36 ± 0.54 2.46 ± 0.91 (mmol/L) 
HDL-C 
1.39 ± 0.17 1.3 ± 0.10 0.347 1.65 ± 0.60 1.61 ± 0.43 (mmol/L) 
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0.600 
0.644 
< 
0.005 
0.733 
0.775 
0.139 
0.017 
0.888 
0.215 
0.005 
0.502 
0.431 
0.861 
0.672 
0.288 
0.244 
0.042 
0.025 
0.786 . 
TC/HDL-C 2.86 ± 0.78 2.54 ± 0.8 0.348 3.52 ± 0.83 2.88 ± 0.57 
PTH '(pmol/L) 6.6 ± 2.2 7.2 ± 2.9 0.486 6.4 ± 2.4 4.1 ± 0.8 
AST (U/L) 24.6 ± 4.7 17.6 ± 5.0 0.037 28.0 ± 22.3 18.3 ± 6.7 
ALT (U/L) 22.0 ± 9.8 17.8 ± 5.0 0.378 30.8 ± 33.0 18.0 ± 9.3 
Serum 
calcium 2.4 ± 0.1 2.4 ± 0.1 0.688 2.3 ± 0.1 2.4 ± 0.0 
(mmol/L) 
Serum 
41.2 ± 3.7 44.2 ± 2.2 0.170 42.3 ± 3.7 42.6 ± 3.2 
albumin (g/L) 
Serum 
creatinine 79.2 ± 14.2 74.2 ± 16.9 0.093 76.3 ± 6.9 70.2 ± 9.0 
(µmol/L) 
eGFR 
(ml/min/1.73m 68.2 ± 14.6 72.0 ± 18.8 0.135 72.3 ± 8.2 75.5 ± 10.1 
2) 
Data presented as means ± SD. BMI; body mass index; WC, waist circumference; HC, hip 
circumference; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; PTH, parathyroid hormone; FSG, fasting serum glucose; HbA1C, glycated hemoglobin 
A1c; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-8, homeostatic 
model assessment of ~-cell function; TC, total cholesterol; LDL-C, low-density lipoprotein 
cholesterol; HDL-C, high-density lipoprotein cholesterol; TC/HDL-C, total cholesterol and high-
density lipoprotein cholesterol ratio; TG; triglycerides; AST, aspartate transaminase; ALT, alanine 
transaminase; a(ld eGFR, estimated glomerular filtration rate. Within group, a paired t-test was 
performed to determine if there were significant differences between values at 3 years vs. 
baseline. P is significant =::;; 0.10. 
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0.048 
0.032 
0.221 
0.265 
0.102 
0.502 
0.031 
0.212 
Table 22: Comparison of outcome measures, presented as means ± SD, in 
participants between groups at 3 years, following retrospective assignment, for 
T2DM subjects (n = 11 ). 
Body weight 93.2 ± 6.7 71.7 ± 15.5 0.019 
BMI (kg/m ) 36.9 ± 1.2 28.4 ± 4.7 0.006 
Total body fat (kg) 20.2 ± 1.5 15.5 ± 3.4 0.018 
Body fat(%) 44.0 ± 1.9 33.0 ± 10.2 0.045 
WC (cm) 105.0 ± 2.8 84.9 ± 25.9 0.116 
HC (cm) 121.9 ± 5.4 107.1 ± 11.7 0.028 
WHR 0.86 ± 0.05 0.89 ± 0.06 0.505 
SBP (mmHg) 141.2 ± 22.9 129.0 ± 15.1 0.316 
DBP(mmHg) 77.6 ± 8.3 84.7 ± 13.9 0.347 
Serum calcidiol (nmol/L) 65.0 ± 18.2 88.7 ±40.0 0.256 
FSG (mmol/L) 6.8 ± 2.5 6.6 ± 2.5 0.889 
Fasting serum insulin (pmol/L) 134.4 ± 127.0 52.3 ±38.3 0.164 
HbA1C(%) 7.8 ± 0.9 8.3 ± 1.49 0.479 
HOMA-IR 31.6 ± 15.1 16.4 ± 15.6 0.139 
HOMA-8 14674 ± 31712 -30 ±823 0.281 
TG (mmol/L) 0.97 ± 0.23 1.05 ±0.34 0.695 
TC (mmol/L) 3.32 ± 1.10 4.55 ± 1.06 0.092 
LDL-C (mmol/L) 1.62 ± 0.95 2.46 ± 0.91 0.168 
HDL-C (mmol/L) 1.3 ± 0.10 1.61 ± 0.43 0.157 
TC/HDL-C 2.54 ± 0.8 2.88 ± 0.57 0.472 
PTH (pmol/L) 7.2 ± 2.9 4.1 ± 0.8 0.079 
AST (U/L) 17.6 ± 5.0 18.3 ± 6.7 0.845 
ALT (U/L) 17.8 ± 5.0 18.0 ± 9.3 0.967 
Serum calcium (mmol/L) 2.4 ± 0.1 2.4 ± 0.0 0.366 
Serum albumin (g/L) 44.2 ± 2.2 42.6 ± 3.2 0.702 
Serum creatinine (µmol/L) 74.2 ± 16.9 70.2 ± 9.0 0.623 
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j eGFR (ml/min/1. 73m2) 72.0 ± 18.8 75.5 ± 10.1 I o.702 I 
Data presented as means ± SD. BMI; body mass index; WC, waist circumference; HC, hip 
circumference; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; PTH, parathyroid hormone; FSG, fasting serum glucose; HbA1C, glycated hemoglobin 
A1c; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-B, homeostatic 
model assessment of ~-cell function; TC, total cholesterol; LDL-C, low-density lipoprotein 
cholesterol; HDL-C, high-density lipoprotein cholesterol; TC/HDL-C, total cholesterol and high-
density lipoprotein cholesterol ratio; TG; triglycerides; AST, aspartate transaminase; ALT, alanine 
transaminase; and eGFR, estimated glomerular filtration rate. An unpaired t-test was performed 
to determine if there were significant differences between values at 3 years in CaD vs. placebo. 
Pis significant S 0.1. 
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Appendix B 
Consent forms 
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YORK 
I! 
UNIVERSIT~ 
·--···-·--·-·-·---·--····-UNIVERSITY 
Research participant Consent Form 
Women's Health in Women's Hands Community Health Centre 
Date: May 25, 2010 
Study Name: The role of vitamin D and calcium supplementation in modulating 
the pathogenesis of type 2 diabetes mellitus (T2DM). 
Researchers: Mazen J Hamadeh, Jesse Solomon, and Shahd-Alabdulkader 
Collaborators: 
Qualified Investigator: Dr. Sonia Malhotra- Women's Health in Women's Hands 
Community Health Centre . 
Sponsors: Mazen J Hamadeh- York University 
Purpose of the Research: To examine the effects of vitamin D and calcium 
supplementation on markers of T2DM (fasting plasma insulin and glucose . 
concentration, insulin resistance, etc.). The study also endeavours to strengthen 
the existing positive correlation between calcium and bone health status 
(parathyroid hormone) and glycemic control (HbA 1 c, fasting plasma glucose and 
insulin, insulin resistance). The dose of 1,800 IU of vitamin D has never been 
studied in men a~d women with type 2 diabetes mellitus and is considered 
experimental. 
Treatment Groups: We expect a total of 120 individuals to participate in the 
study. The probability of being assigned to either the vitamin D & calcium group 
or the placebo group is 50% or less. Your chances of group assignment do not 
change if you are considered to be insufficient in vitamin D .. 
What You Will Be Asked to Do in the Research: Participants will be required 
to 1) have anthropometric measurements taken (height, weight and waist 
circumference, etc.), 2) take a daily supplement containing either 1,800 IU 
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vitamin D and 720 mg of calcium or a placebo for 36 months, 3) have blood 
drawn for analysis of biomarkers (insulin, glucose, parathyroid hormone, 25-
hydroxyvitamin 0 3, calcium, etc.) at baseline, 6, 12, 18, 24, 30 and 36 months. 
Insulin resistance will be calculated at the above time points using the 
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). You will also 
be asked to complete a 3-7 day diet record (a measure of current dietary intake), 
a Diet History Questionnaire (DHQ; a measure of dietary intake over the past 12 
months), and a physical activity log at the same time points mentioned above. 
Risks and Discomforts: We do not foresee any risks or discomfort from your 
participation in the research. 
Benefits of the Research and Benefits to You: The results obtained from this 
clinical study will provide 
us with some insight into the relationship between vitamin D, calcium and T2DM, 
as well as the relationship between T2DM markers and calcium/bone heaith. If 
what we hypothesize is indeed true, then those supplemented with vitamin D 
and calcium will have a decrease in specific biomarkers (plasma insulin and 
glucose, tartrate resistant acid phosphatase-maker of bone breakdown, 
parathyroid hormone) and decreased insulin resistance which are desired 
changes for individuals with T2DM and can improve the metabolic dysregulation 
tha~ occurs in these individl:Jals. In other words, p~tients with T2DM who are 
supplemented with vitamin o·and calcium will have a decrease in the severity of 
the disease. 
Voluntary Participation: Your participation in the study is completely voluntary 
and you may choose to stop participating at any time. Your decision not to 
volunteer will not influence the treatment you may be receiving, or the nature of 
120 
the ongoing relationship you may have with the researchers or study staff, or the 
nature of your relationship with York University or your Community Health 
Centre either now, or in the future. 
Withdrawal from the Study: You can stop participating in the study at any 
time, for any reason, if you so decide. Your decision to stop participating, or to 
refuse to answer particular questions, will not affect your relationship with the 
researchers, York University, or any other group associated with this project. In 
the event you withdraw from the study, all associated data collected will be 
immediately destroyed unless consent is given to include your partial data in the 
study or further analysis. 
Confidentiality: All information you supply during the research will be held in 
confidence and unless you specifically indicate your consent, your name will not 
appear in any report or publication of the research. Your data will be safely 
stored in a locked facility and only research staff will have access to this 
information. All data wifl be stored for the duration of the study plus 25 years 
post-study completion (as per Health Canada's guidelines) and will be archived 
in computer databases with limited access to study collaborators. The 
monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be 
granted direct access to the subject's original medical records for verification of 
clinical trial procedures and/or data, without violating your confidentiality, which 
will be protected to the fullest extent possible by law. 
Compensation: There will be no compensation for adverse events. 
Questions About the Research? If you have questions about the research in 
general or about your role in the study, please feel free to contact Dr. Mazen J 
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Hamadeh either by telephone (416-736-2100 ext. 33552) or e-mail 
(hamadeh@yorku.ca), Shahd Abdulkader (416-520-0191) or email 
(shahda@yorku.ca) or your specific Community Health Centre contact Michelle 
Westin (416 249 8000 x 2258) Lisa Martin RD, COE (416-249-8000), or the 
qualified investigator Dr. Malhotra (416-593-7655 x7). This research has been 
reviewed and approved by the Human Participants Review Sub-Committee, 
York University's Ethics Review Board and conforms to the sta,ndards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions 
about this process, or about your rights as a participant in the study, please 
contact Ms. Alison Collins-Mrakas, Manager, Research Ethics, 309 York Lanes, 
York University (telephone 416-736-5914 or e-mail acollins@yorku.ca). 
Legal Rights and Signatures: 
____________________________________________________________ ,consentto 
participate in, The role of vitamin D and calcium supplementation in modulating 
the pathogenesis of tVPe 2 diabetes mellitus (T2DM). a clinical study conducted 
by Dr. Mazen J Hamadeh. I have understood the nature of this project and wish 
to participate. I am not waiving any of my legal rights by signing this form. My 
signature below indicates my consent. 
·Signature _D_a_te _________ _ 
Participant 
Signature _D_a_te _________ _ 
Dr. Sonia Malhotra Qualified Investigator 
Signature _D_a..;...te _________ _ 
Principal Investigator 
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